Bayesian estimation of gene constraint from an evolutionary model with gene features

Tony Zeng[1,*,†], Jeffrey P. Spence[1,*,†], Hakhamanesh Mostafavi[1], Jonathan K. Pritchard[1,2,†]
[1] Department of Genetics, Stanford University, Stanford CA
[2] Department of Biology, Stanford University, Stanford CA
[*] Equal contribution
† Correspondence to:
tkzeng@stanford.edu, jspence@stanford.edu, pritch@stanford.edu

May 19, 2023

Abstract

Measures of selective constraint on genes have been used for many applications including clinical interpretation of rare coding variants, disease gene discovery, and studies of genome evolution. However, widely-used metrics are severely underpowered at detecting constraint for the shortest ∼25% of genes, potentially causing important pathogenic mutations to be overlooked. We developed a framework combining a population genetics model with machine learning on gene features to enable accurate inference of an interpretable constraint metric, s_{het}. Our estimates outperform existing metrics for prioritizing genes important for cell essentiality, human disease, and other phenotypes, especially for short genes. Our new estimates of selective constraint should have wide utility for characterizing genes relevant to human disease. Finally, our inference framework, GeneBayes, provides a flexible platform that can improve estimation of many gene-level properties, such as rare variant burden or gene expression differences.

1 Introduction

Identifying the genes important for disease and fitness is a central goal in human genetics. One particularly useful measure of importance is how much natural selection constrains a gene [1–4]. Constraint has been used to prioritize *de novo* and rare variants for clinical followup [5,6], predict the toxicity of drugs [7], link GWAS hits to genes [8], and characterize transcriptional regulation [9,10], among many other applications.

To estimate the amount of constraint on a gene, several metrics have been developed using loss-of-function variants (LOFs), such as protein truncating or splice disrupting variants. If a gene is important, then natural selection will act to remove LOFs from the population. Several metrics of gene importance have been developed based on this intuition to take advantage of large exome sequencing studies.

In one line of research, the number of observed unique LOFs is compared to the expected number under a model of no selective constraint. This approach has led to the widely-used metrics pLI [11] and LOEUF [12].

While pLI and LOEUF have proved useful for identifying genes intolerant to LOF mutations, they have important limitations [3]. First, they are uninterpretable in that they are only loosely related to the fitness consequences of LOFs. Their relationship with natural selection depends on the study's sample size and other technical factors [3]. Second, they are not based on an explicit population genetics model so it is impossible to compare a given value of pLI or LOEUF to the strength of selection estimated for variants other than LOFs [3,4].

Another line of research has solved these issues of interpretability by estimating the fitness reduction for heterozygous carriers of an LOF in any given gene [1,2,4]. Throughout, we will adopt the notation of Cassa and colleagues, and refer to this reduction in fitness as s_{het} [1,2], although the same population genetic quantity has been referred to as hs [4,13]. In [1] a deterministic approximation was used to estimate s_{het}, which was relaxed to incorporate the effects of genetic drift in [2]. This model was subsequently extended by Agarwal and colleagues to include the X chromosome and applied to a larger dataset, with a focus on the interpretability of s_{het} [4].

A major issue for most previous methods is that thousands of genes have few expected unique LOFs under neutrality as they have short protein-coding sequences. For example, there are >5,000 genes that cannot be called as constrained by LOEUF, as they have too few expected unique LOFs to fall under the recommended LOEUF cutoff of 0.35 [14]. This problem is not limited to LOEUF, however, and all of these methods are severely underpowered to detect selection for this ∼25% of genes.

Here, we present an approach that can accurately estimate s_{het} even for genes with few expected LOFs, while maintaining the interpretability of previous population-genetics based estimates [1,2,4].

Our approach has two main technical innovations. First, we use a novel population genetics model of LOF allele frequencies. Previous methods have either only modeled the number of unique LOFs, throwing away frequency information [11,12,15], or considered the sum of LOF frequencies across the gene [1,2,4], an approach that is not robust to misannotated LOFs. In contrast, we model the frequencies of individual LOF variants, allowing us to not only use the information

in such frequencies but also to model the possibility that any given LOF variant has been misannotated, making our estimates more robust. Our approach uses new computational machinery, described in a companion paper [16], to accurately obtain the likelihood of observing an LOF at a given frequency without resorting to simulation [2, 4] or deterministic approximations [1].

Second, our approach uses thousands of gene features, including gene expression patterns, protein structure information, and evolutionary constraint, to improve estimates for genes with few expected LOFs. By using these features, we can share information across similar genes. Intuitively, this allows us to improve estimates for genes with few expected LOFs by leveraging information from genes with similar features that do have sufficient LOF data.

Adopting a similar approach, a recent preprint [15] used gene features in a deep learning model to improve estimation of constraint for genes with few expected LOFs, but did not use an explicit population genetics model, resulting in the same issues with interpretability faced by pLI and LOEUF.

We applied our method to a large exome sequencing cohort [12]. Our estimates of s_{het} are substantially more predictive than previous metrics at prioritizing essential and disease-associated genes. We also interrogated the relationship between gene features and natural selection, finding that evolutionary conservation, protein structure, and expression patterns are more predictive of s_{het} than co-expression and protein-protein interaction networks. Expression patterns in the brain and expression patterns during development are particularly predictive of s_{het}. Finally, we use s_{het} to highlight differences in selection on different categories of genes and consider s_{het} in the context of selection on variants beyond LOFs.

Our approach, GeneBayes, is extremely flexible and can be applied to improve estimation of numerous gene properties beyond s_{het}. Our implementation is available at `https://github.com/tkzeng/GeneBayes`.

2 Results

2.1 Model Overview

Using LOF data to infer gene constraint is challenging for genes with few expected LOFs, with metrics like LOEUF considers almost all such genes unconstrained (Figures 1**A**,**B**). We hypothesized that it would be possible to improve estimation using auxiliary information that may be predictive of LOF constraint, including gene expression patterns across tissues, protein structure, and evolutionary conservation. Intuitively, genes with similar features should have similar levels of constraint. By pooling information across groups of similar genes, constraint estimated for genes with sufficient LOF data may help improve estimation for underpowered genes.

However, while the frequencies of LOFs can be related to s_{het} through models from population genetics [1, 2, 4], we lack an understanding of how other gene features relate to constraint *a priori*.



Figure 1: **Limitations of LOEUF and schematic for inferring s_{het} using GeneBayes. A)** *Stacked histogram of the expected number of unique LOFs per gene, where the distribution for genes considered unconstrained (respectively constrained) by LOEUF are colored in red (respectively blue). Genes with LOEUF* < 0.35 *are considered constrained, while all other genes are unconstrained (Methods). The plot is truncated on the x-axis at 100 expected LOFs.* **B)** *Scatterplot of the observed against the expected number of unique LOFs per gene. The dashed line denotes observed* $=$ *expected. Each point is a gene, colored by its LOEUF score; genes with LOEUF* > 1 *are colored as LOEUF* $= 1$. **C)** *Schematic for estimating* s_{het} *using GeneBayes, highlighting the major components of the model: prior (blue boxes) and likelihood (red boxes). Parameters of the prior are learned by maximizing the likelihood (red arrow). Combining the prior and likelihood produces posteriors over* s_{het} *(purple box). See Methods for details.*

To address this problem, we developed a flexible empirical Bayes framework, GeneBayes, that learns the relationship between gene features and s_{het} (Figure 1**C**). Our model consists of two main components. First, we model the prior on s_{het} for each gene as a function of its gene features (Figure 1**C**, left). Specifically, we train gradient-boosted trees using NGBoost [17] to predict the parameters of each gene's prior distribution from its features. Our gene features include gene expression levels, Gene Ontology terms, conservation across species, neural network embeddings of protein sequences, gene regulatory features, co-expression and protein-protein interaction features, sub-cellular localization, and intolerance to missense mutations (see Methods and Supplementary Note C for a full list).

Second, we use a model from population genetics to relate s_{het} to the observed LOF data (Figure 1**C**, right). This model allows us to fit the gradient-boosted trees for the prior by maximizing the likelihood of the LOF data. Specifically, we use the discrete-time Wright Fisher model with genic selection, a standard model in population genetics that accounts for mutation and genetic drift [13, 18]. In our model, s_{het} is the reduction in fitness per copy of an LOF, and we infer s_{het} while keeping the mutation rates and demography fixed to values taken from the literature (Supplementary Note B). Likelihoods are computed using new methods described in a companion paper [16].

Previous methods use either the number of *unique* LOFs or the sum of the frequencies of all LOFs in a gene, but we model the frequency of each individual LOF variant. We used LOF frequencies from the gnomAD consortium, which consists of exome sequences from ∼125,000 individuals for 18,563 genes after filtering.

Combining these two components—the learned priors and the likelihood of the LOF data— we obtained posterior distributions over s_{het} for every gene. Throughout, we use the posterior mean value of s_{het} for each gene as a point estimate. See Methods for more details and Supplementary Table 2 for estimates of s_{het}.

2.2 Population genetics model and gene features both affect the estimation of s_{het}

First, we explored how LOF frequency and mutation rate relate to s_{het} in our population genetics model (Figure 2**A**). Invariant sites with high mutation rates are indicative of strong selection ($s_{\text{het}} > 10^{-2}$), consistent with [19], while such sites with low mutation rates are consistent with essentially any value of s_{het} for the demographic model considered here. Regardless of mutation rate, singletons are consistent with most values of s_{het} but can rule out extremely strong selection, and variants observed at a frequency of >10% rule out even moderately strong selection ($s_{\text{het}} > 10^{-3}$).

To assess how informative gene features are about s_{het}, we trained our model on a subset of genes and evaluated the model on held-out genes (Figure 2**B**, Methods). We computed the Spearman correlation between s_{het} estimates from the prior and s_{het} estimated from the LOF data only. The correlation is high and comparable between train and test sets (Spearman $\rho = 0.83$ and 0.78 respectively), indicating the gene features alone are highly predictive of s_{het} and that this is not a consequence of overfitting.

To further characterize the impact of features on our estimates of s_{het}, we removed all features from our model and recalculated posterior distributions (Figure 2**C**). For most genes, posteriors



Figure 2: **Both the likelihood and prior contribute to s_{het} estimates, and drive differences between s_{het} and LOEUF. A)** *Likelihood curves for different allele frequencies, f, and mutation rates.* **B)** *Scatterplot of s_{het} estimated from LOF data (y-axis; posterior mean from a model without features) against the prior's predictions of s_{het} (x-axis; mean of learned prior). Dotted line denotes $y = x$. Each point is a gene, colored by the expected number of LOFs.* **C)** *Comparison of posterior distributions of s_{het} from models with (blue lines) and without (orange lines) gene features. Genes are ordered by posterior mean (model with gene features).* **D)** *Top: scatterplot of LOEUF (y-axis) and our s_{het} estimates (x-axis; posterior mean). Each point is a gene, colored by the expected number of LOFs. Bottom: scatterplot of s_{het} estimates from [4] (y-axis) and our s_{het} estimates (x-axis). Numbered points refer to genes in panels **E** and **F**.* **E)** *TBC1D3 and PLN are genes where the gene features substantially affect the posterior. We plot the posterior distribution (blue) and the likelihood (orange; rescaled so that the area under the curve = 1).* **F)** *AARD and TWIST1 are genes with the same LOEUF but different s_{het}. Posteriors and likelihoods are plotted as in panel **E**.*

are substantially more concentrated when using gene features.

Next, we compared our estimates of s_{het} using GeneBayes to LOEUF and to selection coefficients estimated by [4] (Figure 2**D**). To facilitate comparison, we use the posterior modes of s_{het} reported in [4] as point estimates, but we note that [4] emphasizes the value of using full posterior distributions. While the correlation between our estimates is high for genes with sufficient LOFs (for genes with more LOFs than the median, Spearman ρ with LOEUF = 0.94; ρ with Agarwal's s_{het} = 0.88), it is lower for genes with few expected LOFs (for genes with fewer LOFs than the median, Spearman ρ with LOEUF = 0.71; ρ with Agarwal's s_{het} = 0.71).

We further explored the reduced correlations for genes with few expected LOFs. For example, *TBC1D3* and *PLN* have few expected LOFs, and their likelihoods are consistent with any level of constraint (Figure 2**E**). Due to the high degree of uncertainty, LOEUF considers both genes to be unconstrained, while the s_{het} point estimates from [4] err in the other direction and consider both genes to be constrained (Figure 2**D**). This behavior for the s_{het} estimates from [4] is due to the high degree of uncertainty from the LOF data alone, which is captured by their wide posterior distributions. In contrast, by using gene features, our posterior distribution of s_{het} indicates that *PLN* is strongly constrained, but *TBC1D3* is not, consistent with the observation that heterozygous LOFs in *PLN* cause severe cardiac dilation and heart failure [20].

In contrast to estimates of s_{het}, LOEUF further ignores information about allele frequencies by considering only the number of unique LOFs, resulting in a loss of information. For example, *AARD* and *TWIST1* have almost the same numbers of observed and expected unique LOFs, so LOEUF is similar for both (LOEUF = 1.1 and 1.06 respectively). However, while *TWIST1*'s observed LOF is present in only 1 of 246,192 alleles, *AARD*'s is $\sim$40$\times$ more frequent. Consequently, the likelihood rules out the possibility of strong constraint at *AARD* (Figure 2**F**), causing the two genes to differ in their estimated selection coefficients (Figure 2**D**).

In contrast, *TWIST1* has a posterior mean s_{het} of 0.11 when using gene features, indicating very strong selection. Consistent with this, TWIST1 is a transcription factor critical for specification of the cranial mesoderm, and heterozygous LOFs in the gene are associated with Saethre-Chotzen syndrome, a disorder characterized by congenital skull and limb abnormalities [21,22].

Besides *PLN* and *TWIST1*, many genes are considered constrained by s_{het} but not by LOEUF, which is designed to be highly conservative. In Table 1, we list 15 examples with $s_{\text{het}} > 0.1$ and LOEUF > 0.5, selected based on their clinical significance and prominence in the literature (Methods). One notable example is a set of 16 ribosomal protein genes for which heterozygous disruption causes Diamond-Blackfan anemia—a rare genetic disorder characterized by an inability to produce red blood cells [23] (Supplementary Table 1). All are considered strongly constrained by s_{het} (minimum $s_{\text{het}} = 0.26$). In contrast, only 6 are considered constrained by LOEUF (LOEUF < 0.35), as many of these genes have few expected unique LOFs.

Gene	s_{het}	LOEUF	Obs.	Exp.	Condition and reference
*RPS15A**	0.61	0.56	0	5.4	*Diamond-Blackfan anemia*: Red blood cell aplasia resulting in growth, craniofacial, and other congenital defects [23]
DCX	0.48	0.62	3	12.6	*Lissencephaly*: Migrational arrest of neurons resulting in mental retardation and seizures [24]
SOX2	0.33	0.57	1	8.3	*Syndromic microphthalmia*: Missing or small eyes from birth [25]
NDP	0.33	0.88	0	3.4	*Norrie disease*: Retinal dystrophy resulting in early childhood blindness, mental disorders, and deafness [26]
EIF5A	0.32	0.54	1	8.7	*Faundes-Banka syndrome*: Developmental delay, microcephaly, and facial dysmorphisms [27]
CDKN1C	0.27	0.53	0	5.7	*Beckwith-Wiedemann syndrome*: Pediatric overgrowth with predisposition to tumor development [28]
TGIF1	0.25	0.91	5	11.5	*Holoprosencephaly*: Structural malformation of the forebrain during development [29]
SH2D1A	0.23	0.96	1	4.9	*Lymphoproliferative syndrome*: Severe immune dysregulation due to improper lymphocyte apoptosis [30]
CEBPA	0.17	1.18	0	2.4	*Acute myeloid leukemia*: Blood and bone marrow cancer with rapid progression [31]
GATA4	0.15	0.53	3	14.7	*Atrial septal defect*: Congenital heart defect resulting in a hole between the atria [32]
TIMP3	0.13	0.53	2	11.8	*Sorsby fundus dystrophy*: Retinal dystrophy that causes loss of vision [33]
FOXC2	0.13	0.79	3	9.8	*Lymphedema-distichiasis syndrome*: Lymphedema of the limbs and double rows of eyelashes [34]
IGF2	0.12	1.13	3	6.8	*Silver-Russell syndrome*: Growth retardation, relative macrocephaly, and feeding difficulties [35]
PLN	0.12	1.56	0	1.5	*Dilated cardiomyopathy*: Enlarged heart chambers, decreased contractile function, and heart failure [20]
TWIST1	0.11	1.06	1	4.5	*Saethre-Chotzen syndrome*: Craniosynostosis, facial dysmorphism, and hand and foot abnormalities [21] [22]

Table 1: **OMIM genes constrained by s_{het} but not LOEUF.** *Mutations that disrupt the functions of these genes are associated with Mendelian diseases in the OMIM database [36] Genes are ordered by s_{het}. Obs. and Exp. are the unique number of observed and expected LOFs respectively. *RPS15A is associated with Diamond-Blackfan anemia along with nine other genes considered constrained by s_{het} but not by LOEUF (Supplementary Table 1).*

2.3 Utility of s_{het} in prioritizing phenotypically important genes

To assess the accuracy of our s_{het} estimates and evaluate their ability to prioritize genes, we first used these estimates to distinguish between genes essential and non-essential for survival of human cells *in vitro*. Genome-wide CRISPR growth screens have measured the effects of gene knockouts on cell survival or proliferation, quantifying the *in vitro* importance of each gene for fitness [37, 38]. We find that our estimates of s_{het} outperform other constraint metrics at classifying essential genes (Figure 3**A**, left; bootstrap $p < 2 \times 10^{-5}$ for pairwise differences in AUPRC between our estimates and other metrics). The difference is largest for genes with few expected LOFs, where s_{het} (GeneBayes) retains similar precision and recall while other metrics lose performance (Figure 3**A**, right). In addition, our estimates of s_{het} outperform other metrics at classifying nonessential genes (Supplementary Figure 2**A**).

DeepLOF [15], is the only other method that combines information from both LOF data and gene features, and outperforms methods that rely exclusively on LOF data, highlighting the im-



Figure 3: **GeneBayes estimates of s_{het} perform well at identifying constrained genes. A)** *Precision-recall curves comparing the performance of* s_{het} *against other methods in classifying essential genes (left: all genes, right: quartile of genes with the fewest expected unique LOFs).* **B)** *Precision-recall curves comparing the performance of* s_{het} *against LOEUF in classifying developmental disorder genes.* **C)** *Scatterplots showing the enrichment (respectively depletion) of the top 10% most (respectively least) constrained genes in HPO terms, with genes ranked by* s_{het} *(y-axis) or LOEUF (x-axis).* **D)** *Enrichment of* de novo *mutations in patients with developmental disorders, calculated as the observed number of mutations over the expected number under a null mutational model. We plot the enrichment of missense, splice, and nonsense variants in the 10% most constrained genes, ranked by* s_{het} *(blue) or LOEUF (orange). Bars represent 95% confidence intervals.* **E)** *Left: LOESS curve showing the relationship between constraint (gene rank, x-axis) and absolute log fold change in expression between chimp and human cortical cells (y-axis). Genes are ranked by* s_{het} *(blue) or LOEUF (orange) Right: LOESS curve showing the relationship between constraint (gene rank, x-axis) and gene expression variation (normalized standard deviation) in GTEx samples.*

portance of using auxiliary information. Yet, DeepLOF uses only the number of unique LOFs,

discarding frequency information. As a result, it is outperformed by our method, indicating that careful modeling of LOF frequencies also contributes to the performance of our approach.

Next, we performed further comparisons of our estimates of s_{het} against LOEUF, as LOEUF and its predecessor pLI are extremely popular metrics of constraint. To evaluate the ability of these methods to prioritize disease genes, we first used s_{het} and LOEUF to classify curated developmental disorder genes from genes without known associations with developmental disorders [39]. Here, s_{het} outperforms LOEUF (Figure 3**B**; bootstrap $p = 2 \times 10^{-9}$ for the difference in AUPRC) and performs favorably compared to additional constraint metrics (Supplementary Figure 2**B**).

Next, we considered a broader range of phenotypic abnormalities annotated in the Human Phenotype Ontology (HPO) [40]. For each HPO term, we calculated the enrichment of the 10% most constrained genes and depletion of the 10% least constrained genes, ranked using s_{het} or LOEUF. Genes considered constrained by s_{het} are 1.9-fold enriched in HPO terms, compared to 1.5-fold enrichment for genes considered constrained by LOEUF (Figure 3**C**, left). Additionally, genes considered unconstrained by s_{het} are 3.0-fold depleted in HPO terms, compared to 2.1-fold depletion for genes considered constrained by LOEUF (Figure 3**C**, right).

X-linked inheritance is one of the terms with the largest enrichment of constrained genes (6.6-fold enrichment for s_{het} and 4.2-fold enrichment for LOEUF). The ability of s_{het} to prioritize X-linked genes may prove particularly useful, as many disorders are enriched for X-chromosome genes [41] and the selection on losing a single copy of such genes is stronger on average [4]. Yet, population-scale sequencing alone has less power to detect a given level of constraint on X-chromosome genes, as the number of X chromosomes in a cohort with males is smaller than the number of autosomes.

We next assessed if *de novo* disease-associated variants are enriched in constrained genes, similar to the analyses in [4,5]. To this end, we used data from 31,058 trios to calculate for each gene the enrichment of *de novo* missense and LOF mutations in offspring with DDs relative to unaffected parents [5]. We found that for both classes of variants, enrichment is higher for genes considered constrained by s_{het}, with the highest enrichment observed for LOF variants (Figure 3**D**; enrichment of s_{het} and LOEUF respectively, for missense mutations = 2.2, 1.9; splice site mutations = 6.3, 4.6; and nonsense mutations = 9.5, 6.7). Consistent with previous findings, the excess burden of *de novo* variants is predominantly in highly constrained genes (Supplementary Figure 2**C**). Notably, this difference in enrichment remains after removing known DD genes (Supplementary Figure 2**C**). Together, these results indicate that s_{het} not only improves identification of known disease genes but may also facilitate discovery of novel DD genes [5].

Finally, constraint can also be related to longer-term evolutionary processes that give rise to the variation among individuals or species, including variation in gene expression levels. We expect genes for which LOFs are constrained to maintain expression levels closer to their optimal values across evolutionary time scales, as each LOF can be thought of as a $\sim$50% reduction in expression. Consistent with this expectation, we find that genes with larger absolute differences in expression between human and chimpanzee in cortical cells [42] (Methods) are less constrained, with a stronger correlation for s_{het} than for LOEUF (Figure 3**E**). This pattern should also hold when considering the variation in expression within a species. We quantified variance using the normalized standard deviation of gene expression levels estimated from RNA-seq samples in GTEx [43]

(Methods) and found that the variance decreases with increased constraint, again with a stronger correlation for s_{het} (Figure 3**E**).



Figure 4: **Breakdown of the gene features important for s_{het} prediction. A)** *Ordered from highest to lowest, plot of the mean per-gene log likelihood over the test genes for models separately trained on categories of features. "All" and "Baseline" include all and no features respectively.* **B)** *Plot of the mean per-gene log likelihood, as in panel* ***A****, for models separately trained on expression features grouped by tissue, cell type, or developmental stage.* **C)** *Ordered from highest to lowest, feature scores for individual gene ontology (GO) terms. Inset: lineplot showing the change in predicted s_{het} for a feature as the feature value is varied.* **D)** *Lineplot as in panel* ***C*** *(inset) for protein-protein interaction (PPI) and co-expression features,* **E)** *enhancer and promoter features, and* **F)** *gene structure features.*

2.4 Interpreting the learned relationship between gene features and s_{het}

Our framework allows us to learn the relationship between gene features and s_{het} in a statistically principled way. In particular, by fitting a model with all of the features jointly, we can account for dependencies between the features. To interrogate the relationship between features and s_{het}, we divided our gene features into 10 distinct categories (Figure 4**A**) and trained a separate model per category using only the features in that category. We found that missense constraint, expression patterns across tissues, evolutionary conservation, and protein embeddings are the most informative categories.

Next, we further divided the expression features into 24 subgroups, representing tissues, cell types, and developmental stage (Table 6). Expression patterns in the brain, digestive system, and during development are the most predictive of constraint (Figure 4**B**). Notably, a study that matched Mendelian disorders to tissues through literature review found that a sizable plurality affect the brain [44]. Meanwhile, most of the top digestive expression features are also related to development (e.g., expression component loadings in a fetal digestive dataset [45]). The importance of developmental features is consistent with the severity of many developmental disorders and the expectation that selection is stronger on early-onset phenotypes [46], consistent with the findings of [4].

To quantify the relationship between constraint and individual features, we changed the value of one feature at a time and used the variation in predicted s_{het} over the feature values as the score for each feature (Methods).

We first explored some of the individual Gene Ontology (GO) terms most predictive of constraint (Figure 4**C**). Consistent with the top expression features, the top GO features highlight developmental and brain-specific processes as important for selection.

Next, we analyzed network (Figure 4**D**), gene regulatory (Figure 4**E**), and gene structure (Figure 4**F**) features. Protein-protein interaction (PPI) and gene co-expression networks have highlighted "hub" genes involved in numerous cellular processes [47,48], while genes linked to GWAS variants have more complex enhancer landscapes [49]. Consistent with these studies, we find that connectedness in PPI and co-expression networks as well as enhancer and promoter count are positively associated with constraint (Figure 4**D**,**E**). In addition, gene structure is associated with function—for example, UTR length and GC content affect RNA stability, translation, and localization [50, 51]—and likewise, several gene structure features are predictive of constraint (Figure 4**F**). Our results indicate that more complex genes—genes that are involved in more regulatory connections, that are more central to networks, and that have more complex gene structures—are generally more constrained.

2.5 Contextualizing the strength of selection against gene loss-of-function

A major benefit of s_{het} over LOEUF and pLI is that s_{het} has a precise, intrinsic meaning in terms of fitness [1–4]. This facilitates comparison of s_{het} between genes, populations, species, and studies. For example, s_{het} can be compared to selection estimated from mutation accumulation or gene deletion experiments performed in model organisms [52,53]. More broadly, selection applies beyond LOFs. While we focused on estimating changes in fitness due to LOFs, consequences of



Figure 5: **Comparing selection on LOFs (s_{het}) between genes and to selection on other variant types. A)** *Distributions of s_{het} for gene sets, calculated by averaging the posterior distributions for the genes in each gene set (Methods). Gene sets are sorted by the mean of their distribution. Colors represent four general selection regimes.* **B)** *Posterior distributions of s_{het} for individual genes, ordered by mean. Lines represent 95% credible intervals, with labeled genes represented by thick black lines. Colors represent the selection regimes in panel* ***A****.* **C)** *Schematic demonstrating the hypothesized relationship between changes in expression (x-axis, $\log_2$ scale) and selection (y-axis) against these changes for two hypothetical genes, assuming stabilizing selection. The shapes of the curves are not estimated from real data. Background colors represent the selection regimes in panel* ***A****. The red points and line represent the effects of heterozygous LOFs and deletions on expression and selection, while the blue points and line represent the potential effects of other types of variants.*

non-coding, missense, and copy number variants can be understood through the same framework, as we expect such variants to also be under negative selection [19] due to ubiquitous stabilizing selection on traits [54]. Quantifying differences in the selection on variants will deepen our understanding of the evolution and genetics of human traits (see Discussion).

To contextualize our s_{het} estimates, we compared the distributions of s_{het} for different gene sets (Figure 5**A**) and genes (Figure 5**B**), and analyzed them in terms of selection regimes. To define such regimes, we first conceptualized selection on variants as a function of their effects on expression (Figure 5**C**), where heterozygous LOFs reduce expression by ∼50% across all contexts relevant for selection. Under this framework, we can directly compare s_{het} to selection on other variant types—for the hypothetical genes in Figure 5**C**, a GWAS hit affecting Gene 1 has a stronger selective effect than a LOF affecting Gene 2 despite having a smaller effect on expression.

Next, we divided the range of possible s_{het} values into four regimes determined by theoretical considerations [55] and comparisons to other types of variants [56, 57]—nearly neutral (9% of genes), weak selection (22%), strong selection (54%), and extreme selection (15%). LOFs in nearly neutral genes ($s_{\text{het}} < 10^{-4}$) have minimal effects on fitness—the frequency of such variants is dominated by genetic drift rather than selection [55]. Under the weak selection regime (s_{het} from 10^{-4} to 10^{-3}), gene LOFs have similar effects on fitness as typical GWAS hits, which usually have small or context-specific effects on gene expression or function [56]. Under the strong selection regime (s_{het} from 10^{-3} to 10^{-1}), gene LOFs have fitness effects on par with the strongest selection coefficients measured for common variants, such as that estimated for adaptive mutations in *LCT* [57]. Finally, for genes in the extreme selection regime ($s_{\text{het}} > 10^{-1}$), LOFs have an effect on fitness equivalent to a >2% chance of embryonic lethality, indicating that such LOFs have an extreme effect on survival or reproduction.

Gene sets vary widely in their constraint. For example, genes known to be haploinsufficient for severe diseases are almost all under extreme selection. In contrast, genes that can tolerate homozygous LOFs are generally under weak selection. One notable example of such a gene is *LPA*—while high expression levels are associated with cardiovascular disease, low levels have minimal phenotypic consequences [58, 59], consistent with limited conservation in the sequence or gene expression of *LPA* across species and populations [60, 61]

Other gene sets have much broader distributions of s_{het} values. For example, manually curated recessive genes are under weak to strong selection, indicating that many such genes are either not fully recessive or have pleiotropic effects on other traits under selection. For example, homozygous LOFs in *PROC* can cause life-threatening congenital blood clotting [62], yet s_{het} for *PROC* is non-negligible (Figure 5**B**), consistent with observations that heterozygous LOFs can also increase blood clotting and cause deep vein thrombosis [63].

Similarly, s_{het} values for ClinVar disease genes [64] span the range from weak to extreme selection, with only moderate enrichment for greater constraint relative to all genes. Consistent with this, the effects of disease on fitness depend on disease severity, age-of-onset, and prevalence throughout human history. For example, even though heterozygous loss of *BRCA1* greatly increases risk of breast and ovarian cancer [65], *BRCA1* is under strong rather than extreme selection. Possible partial explanations are that these cancers have an age-of-onset past reproductive age and are less prevalent in males, or that *BRCA1* is subject to some form of antagonistic pleiotropy [14, 66].

3 Discussion



Figure 6: **GeneBayes is a flexible framework for estimating gene-level properties.** *Schematic for how GeneBayes can be applied to estimate gene-level properties beyond s_{het}, showing the key inputs and outputs and two example applications.*

Here, we developed an empirical Bayes approach to accurately infer s_{het}, an interpretable metric of gene constraint. Our approach uses powerful machine learning methods to leverage vast amounts of functional and evolutionary information about each gene while coupling them to a population genetics model.

There are two advantages of this approach. First, the additional data sources result in substantially better performance than LOEUF across tasks, from classifying essential genes to identifying pathogenic *de novo* mutations. These improvements are especially pronounced for the large fraction of genes with few expected LOFs, where LOF data alone is underpowered for estimating constraint.

Second, by inferring s_{het}, our estimates of constraint are interpretable in terms of fitness, and we can directly compare the impact of a loss-of-function across genes, populations, species, and studies.

As a selection coefficient, s_{het} can also be directly compared to other selection coefficients, even for different types of variants [3, 4]. In general, we believe genes are close to their optimal levels of expression and experience stabilizing selection [54], in which case expression-altering variants decrease fitness, with larger perturbations causing greater decreases (Figure 5**C**). Estimating the fitness consequences of other types of expression-altering variants, such as duplications or eQTLs, will allow us to map the relationship between genetic variation and fitness in detail, deepening our understanding of the interplay of expression, complex traits, and fitness [10, 56, 67, 68].

A recent method, DeepLOF [15], uses a similar empirical Bayes approach, but by estimating constraint from the number of observed and expected unique LOFs, it inherits the same difficulties regarding interpretation as pLI and LOEUF, and loses information by not considering variant frequencies. On the other hand, another line of work [1, 2], culminating in [4], solved the issues with interpretability by directly estimating s_{het}. Yet, by relying exclusively on LOFs, these estimates are underpowered for $\sim$25% of genes. Furthermore, by using the aggregate frequencies of all LOF variants, previous s_{het} estimates [1, 2, 4] are not robust to misannotated LOF variants. Our approach eliminates this tradeoff between power and interpretability present in existing metrics.

Our estimates of s_{het} will be useful for many applications. For example, by informing gene-level priors, LOEUF, pLI, and previous estimates of s_{het} have been used to increase the power of association studies based on rare or *de novo* mutations [5,6]. In such contexts, our s_{het} estimates can be used as a drop-in replacement. Additionally, extremely constrained and unconstrained genes may be interesting to study in their own right. Genes of unknown function with particularly high values of s_{het} should be prioritized for further study. Investigating highly constrained genes may give insights into the mechanisms by which cellular and organism-level phenotypes affect fitness [69].

While we primarily used the posterior means of s_{het} here, our approach provides the entire posterior distribution per gene, similar to [4]. In some applications, different aspects of the posterior may be more relevant than the mean. For example, when prioritizing rare variants for followup in a clinical setting, the posterior probability that s_{het} is high enough for the variant to severely reduce fitness may be more relevant.

As more exomes are sequenced, one might expect that we would be better able to more accurately estimate s_{het}. Yet, in a companion paper [16] we show that increasing the sample size used for estimating LOF frequencies will provide essentially no additional information for the $\sim$85% of genes with the lowest values of s_{het}. This fundamental limit on how much we can learn about these genes from LOF data alone highlights the importance of approaches like ours that can leverage additional data types. By sharing information across genes, we can overcome this fundamental limit on how accurately we can estimate constraint.

Here we focused on estimating s_{het}, but our empirical Bayes framework, GeneBayes, can be used in any setting where one has a model that ties a gene-level parameter to gene-level observable data (Supplementary Note D). For example, GeneBayes can be used to find trait-associated genes using variants from case/control studies [70, 71], or to improve power to find differentially expressed genes in RNA-seq experiments [72]. We provide a graphical overview of how GeneBayes can be applied more generally in Figure 6. Briefly, GeneBayes requires users to input a likelihood model for their parameter of interest. Then, using empirical Bayes and a set of gene features, it improves power to estimate the parameter by flexibly sharing information across similar genes.

In summary, we developed a powerful framework for estimating a broadly applicable and readily interpretable metric of constraint, s_{het}. Our estimates provide a more informative ranking of gene importance than existing metrics, and our approach allows us to interrogate potential causes and consequences of natural selection.

Acknowledgements

We would like to thank Ipsita Agarwal, Molly Przeworski, Jesse Engreitz, and members of the Pritchard Lab for valuable feedback and discussions. This work was supported by NIH grants R01HG011432 and R01HG008140.

References

[1] Cassa CA, Weghorn D, Balick DJ, Jordan DM, Nusinow D, Samocha KE, et al. Estimating the selective effects of heterozygous protein-truncating variants from human exome data. Nature Genetics. 2017;49(5):806-10.

[2] Weghorn D, Balick DJ, Cassa C, Kosmicki JA, Daly MJ, Beier DR, et al. Applicability of the Mutation–Selection Balance Model to Population Genetics of Heterozygous Protein-Truncating Variants in Humans. Molecular Biology and Evolution. 2019;36(8):1701-10.

[3] Fuller ZL, Berg JJ, Mostafavi H, Sella G, Przeworski M. Measuring intolerance to mutation in human genetics. Nature Genetics. 2019;51(5):772-6.

[4] Agarwal I, Fuller ZL, Myers SR, Przeworski M. Relating pathogenic loss-of function mutations in humans to their evolutionary fitness costs. eLife. 2023;12:e83172.

[5] Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature. 2020;586(7831):757-62.

[6] Fu JM, Satterstrom FK, Peng M, Brand H, Collins RL, Dong S, et al. Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. Nature Genetics. 2022;54(9):1320-31.

[7] Whiffin N, Armean IM, Kleinman A, Marshall JL, Minikel EV, Goodrich JK, et al. The effect of LRRK2 loss-of-function variants in humans. Nature Medicine. 2020;26(6):869-77.

[8] Gazal S, Weissbrod O, Hormozdiari F, Dey KK, Nasser J, Jagadeesh KA, et al. Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nature Genetics. 2022;54(6):827-36.

[9] Wang X, Goldstein DB. Enhancer domains predict gene pathogenicity and inform gene discovery in complex disease. The American Journal of Human Genetics. 2020;106(2):215-33.

[10] Mostafavi H, Spence JP, Naqvi S, Pritchard JK. Limited overlap of eQTLs and GWAS hits due to systematic differences in discovery. bioRxiv. 2022:2022-05.

[11] Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-91.

[12] Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-43.

[13] Gillespie JH. Population genetics: a concise guide. JHU press; 2004.

[14] Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: Lessons from gnomAD. Human Mutation. 2022;43(8):1012-30.

[15] LaPolice TM, Huang YF. A deep learning framework for predicting human essential genes from population and functional genomic data. bioRxiv. 2021:2021-12.

[16] Spence J, Zeng T, Mostafavi H, Pritchard J. Scaling the discrete-time Wright-Fisher model to biobank-scale datasets. bioRxiv. 2023.

[17] Duan T, Anand A, Ding DY, Thai KK, Basu S, Ng A, et al. Ngboost: Natural gradient boosting for probabilistic prediction. In: International Conference on Machine Learning. PMLR; 2020. p. 2690-700.

[18] Ewens WJ. Mathematical population genetics: theoretical introduction. vol. 27. Springer; 2004.

[19] Agarwal I, Przeworski M. Mutation saturation for fitness effects at human CpG sites. eLife. 2021;10:e71513.

[20] Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. The Journal of Clinical Investigation. 2003;111(6):869-76.

[21] Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Luna RIOD, et al. Mutations in TWIST, a basic helix–loop–helix transcription factor, in Saethre-Chotzen syndrome. Nature Genetics. 1997;15(1):36-41.

[22] Ghouzzi VE, Merrer ML, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, et al. Mutations of the TWIST gene in the Saethre-Chotzene syndrome. Nature Genetics. 1997;15(1):42-6.

[23] Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood. 2020;136(11):1262-73.

[24] des Portes V, Pinard JM, Billuart P, Vinet MC, Koulakoff A, Carrié A, et al. A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome. Cell. 1998;92(1):51-61.

[25] Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JRO, Howard-Peebles PN, et al. Mutations in SOX2 cause anophthalmia. Nature Genetics. 2003;33(4):462-3.

[26] Berger W, de Pol Dv, Warburg M, Gal A, Bleeker-Wagemakers L, de Silva H, et al. Mutations in the candidate gene for Norrie disease. Human Molecular Genetics. 1992;1(7):461-5.

[27] Faundes V, Jennings MD, Crilly S, Legraie S, Withers SE, Cuvertino S, et al. Impaired eIF5A function causes a Mendelian disorder that is partially rescued in model systems by spermidine. Nature Communications. 2021;12(1):833.

[28] Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, et al. An imprinted gene p57 KIP2 is mutated in Beckwith–Wiedemann syndrome. Nature Genetics. 1996;14(2):171-3.

[29] Gripp KW, Wotton D, Edwards MC, Roessler E, Ades L, Meinecke P, et al. Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination. Nature Genetics. 2000;25(2):205-8.

[30] Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genetics. 1998;20(2):129-35.

[31] Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. New England Journal of Medicine. 2004;351(23):2403-7.

[32] Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003;424(6947):443-7.

[33] Langton KP, McKie N, Curtis A, Goodship JA, Bond PM, Barker MD, et al. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. Journal of Biological Chemistry. 2000;275(35):27027-31.

[34] Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. The American Journal of Human Genetics. 2000;67(6):1382-8.

[35] Begemann M, Zirn B, Santen G, Wirthgen E, Soellner L, Büttel HM, et al. Paternally inherited IGF2 mutation and growth restriction. New England Journal of Medicine. 2015;373(4):349-56.

[36] Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM. org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Research. 2015;43(D1):D789-98.

[37] Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nature Genetics. 2017;49(12):1779-84.

[38] Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald III ER, et al. Next-generation characterization of the cancer cell line encyclopedia. Nature. 2019;569(7757):503-8.

[39] Wright CF, Campbell P, Eberhardt RY, Aitken S, Perrett D, Brent S, et al. Genomic Diagnosis of Rare Pediatric Disease in the United Kingdom and Ireland. New England Journal of Medicine. 2023.

[40] Köhler S, Gargano M, Matentzoglu N, Carmody LC, Lewis-Smith D, Vasilevsky NA, et al. The human phenotype ontology in 2021. Nucleic Acids Research. 2021;49(D1):D1207-17.

[41] Leitão E, Schröder C, Parenti I, Dalle C, Rastetter A, Kühnel T, et al. Systematic analysis and prediction of genes associated with monogenic disorders on human chromosome X. Nature Communications. 2022;13(1):6570.

[42] Agoglia RM, Sun D, Birey F, Yoon SJ, Miura Y, Sabatini K, et al. Primate cell fusion disentangles gene regulatory divergence in neurodevelopment. Nature. 2021;592(7854):421-7.

[43] Consortium G. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369(6509):1318-30.

[44] Basha O, Argov CM, Artzy R, Zoabi Y, Hekselman I, Alfandari L, et al. Differential network analysis of multiple human tissue interactomes highlights tissue-selective processes and genetic disorder genes. Bioinformatics. 2020;36(9):2821-8.

[45] Gao S, Yan L, Wang R, Li J, Yong J, Zhou X, et al. Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencing. Nature Cell Biology. 2018;20(6):721-34.

[46] Charlesworth B, et al. Evolution in age-structured populations. vol. 2. Cambridge University Press Cambridge; 1994.

[47] Barrio-Hernandez I, Schwartzentruber J, Shrivastava A, Del-Toro N, Gonzalez A, Zhang Q, et al. Network expansion of genetic associations defines a pleiotropy map of human cell biology. Nature Genetics. 2023:1-10.

[48] Van Dam S, Vosa U, van der Graaf A, Franke L, de Magalhaes JP. Gene co-expression analysis for functional classification and gene–disease predictions. Briefings in Bioinformatics. 2018;19(4):575-92.

[49] Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021;593(7858):238-43.

[50] Mayr C. Regulation by 3′-untranslated regions. Annual Review of Genetics. 2017;51:171-94.

[51] Leppek K, Das R, Barna M. Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them. Nature Reviews Molecular Cell Biology. 2018;19(3):158-74.

[52] Agrawal AF, Whitlock MC. Inferences about the distribution of dominance drawn from yeast gene knockout data. Genetics. 2011;187(2):553-66.

[53] Mukai T, Chigusa SI, Mettler L, Crow JF. Mutation rate and dominance of genes affecting viability in Drosophila melanogaster. Genetics. 1972;72(2):335-55.

[54] Sella G, Barton NH. Thinking about the evolution of complex traits in the era of genome-wide association studies. Annual Review of Genomics and Human Genetics. 2019;20:461-93.

[55] Charlesworth B. Effective population size and patterns of molecular evolution and variation. Nature Reviews Genetics. 2009;10(3):195-205.

[56] Simons YB, Mostafavi H, Smith CJ, Pritchard JK, Sella G. Simple scaling laws control the genetic architectures of human complex traits. bioRxiv. 2022:2022-10.

[57] Mathieson I, Terhorst J. Direct detection of natural selection in Bronze Age Britain. Genome Research. 2022;32(11-12):2057-67.

[58] Emdin CA, Khera AV, Natarajan P, Klarin D, Won HH, Peloso GM, et al. Phenotypic characterization of genetically lowered human lipoprotein (a) levels. Journal of the American College of Cardiology. 2016;68(25):2761-72.

[59] Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein (a) levels and risk of disease in a large, contemporary, general population study. European Heart Journal. 2021;42(12):1147-56.

[60] Rausell A, Luo Y, Lopez M, Seeleuthner Y, Rapaport F, Favier A, et al. Common homozygosity for predicted loss-of-function variants reveals both redundant and advantageous effects of dispensable human genes. Proceedings of the National Academy of Sciences. 2020;117(24):13626-36.

[61] Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(1):e48-60.

[62] Millar DS, Johansen B, Berntorp E, Minford A, Bolton-Maggs P, Wensley R, et al. Molecular genetic analysis of severe protein C deficiency. Human Genetics. 2000;106:646-53.

[63] Romeo G, Hassan HJ, Staempfli S, Roncuzzi L, Cianetti L, Leonardi A, et al. Hereditary thrombophilia: identification of nonsense and missense mutations in the protein C gene. Proceedings of the National Academy of Sciences. 1987;84(9):2829-32.

[64] Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Research. 2020;48(D1):D835-44.

[65] Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science. 2014;343(6178):1466-70.

[66] Smith KR, Hanson HA, Hollingshaus MS. BRCA1 and BRCA2 mutations and female fertility. Current Opinion in Obstetrics & Gynecology. 2013;25(3):207.

[67] O'Connor LJ, Schoech AP, Hormozdiari F, Gazal S, Patterson N, Price AL. Extreme polygenicity of complex traits is explained by negative selection. The American Journal of Human Genetics. 2019;105(3):456-76.

[68] Benton ML, Abraham A, LaBella AL, Abbot P, Rokas A, Capra JA. The influence of evolutionary history on human health and disease. Nature Reviews Genetics. 2021;22(5):269-83.

[69] Gardner EJ, Neville MD, Samocha KE, Barclay K, Kolk M, Niemi ME, et al. Reduced reproductive success is associated with selective constraint on human genes. Nature. 2022;603(7903):858-63.

[70] He X, Sanders SJ, Liu L, De Rubeis S, Lim ET, Sutcliffe JS, et al. Integrated model of de novo and inherited genetic variants yields greater power to identify risk genes. PLoS Genetics. 2013;9(8):e1003671.

[71] Zhu X, Stephens M. Bayesian large-scale multiple regression with summary statistics from genome-wide association studies. The Annals of Applied Statistics. 2017;11(3):1561.

[72] Boyeau P, Regier J, Gayoso A, Jordan MI, Lopez R, Yosef N. An empirical Bayes method for differential expression analysis of single cells with deep generative models. bioRxiv. 2022:2022-05.

[73] Schiffels S, Durbin R. Inferring human population size and separation history from multiple genome sequences. Nature Genetics. 2014;46(8):919-25.

[74] Cummings BB, Karczewski KJ, Kosmicki JA, Seaby EG, Watts NA, Singer-Berk M, et al. Transcript expression-aware annotation improves rare variant interpretation. Nature. 2020;581(7809):452-8.

[75] McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The ensembl variant effect predictor. Genome Biology. 2016;17(1):1-14.

[76] Frankish A, Carbonell-Sala S, Diekhans M, Jungreis I, Loveland JE, Mudge JM, et al. GENCODE: reference annotation for the human and mouse genomes in 2023. Nucleic Acids Research. 2023;51(D1):D942-9.

[77] Olson ND, Wagner J, McDaniel J, Stephens SH, Westreich ST, Prasanna AG, et al. PrecisionFDA Truth Challenge V2: Calling variants from short and long reads in difficult-to-map regions. Cell Genomics. 2022;2(5):100129.

[78] Blake JA, Baldarelli R, Kadin JA, Richardson JE, Smith CL, Bult CJ. Mouse Genome Database (MGD): Knowledgebase for mouse–human comparative biology. Nucleic Acids Research. 2021;49(D1):D981-7.

[79] Groza T, Gomez FL, Mashhadi HH, Muñoz-Fuentes V, Gunes O, Wilson R, et al. The International Mouse Phenotyping Consortium: comprehensive knockout phenotyping underpinning the study of human disease. Nucleic acids research. 2023;51(D1):D1038-45.

[80] Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Molecular Systems Biology. 2014;10(7):733.

[81] Blomen VA, Májek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, Staring J, et al. Gene essentiality and synthetic lethality in haploid human cells. Science. 2015;350(6264):1092-6.

[82] Samocha KE, Robinson EB, Sanders SJ, Stevens C, Sabo A, McGrath LM, et al. A framework for the interpretation of de novo mutation in human disease. Nature Genetics. 2014;46(9):944-50.

[83] Zeng T, Spence JP, Mostafavi H, Pritchard JK. s_het estimates from GeneBayes and other supplementary datasets. Zenodo; 2023. Available from: `https://doi.org/10.5281/zenodo.7939768`.

[84] Amari Si. Natural Gradient Works Efficiently in Learning. Neural Computation. 1998;10(2):251-76.

[85] Paszke A, Gross S, Massa F, Lerer A, Bradbury J, Chanan G, et al. Pytorch: An imperative style, high-performance deep learning library. Advances in Neural Information Processing Systems. 2019;32.

[86] Loshchilov I, Hutter F. Decoupled weight decay regularization. arXiv preprint arXiv:171105101. 2017.

[87] Gómez P, Toftevaag HH, Meoni G. torchquad: Numerical Integration in Arbitrary Dimensions with PyTorch. Journal of Open Source Software. 2021;6(64):3439.

[88] Chen T, Guestrin C. Xgboost: A scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; 2016. p. 785-94.

[89] Sawyer SA, Hartl DL. Population genetics of polymorphism and divergence. Genetics. 1992;132(4):1161-76.

[90] Harpak A, Bhaskar A, Pritchard JK. Mutation rate variation is a primary determinant of the distribution of allele frequencies in humans. PLoS Genetics. 2016;12(12):e1006489.

[91] Varin C, Reid N, Firth D. An overview of composite likelihood methods. Statistica Sinica. 2011:5-42.

[92] Ramoni RB, Mulvihill JJ, Adams DR, Allard P, Ashley EA, Bernstein JA, et al. The undiagnosed diseases network: accelerating discovery about health and disease. The American Journal of Human Genetics. 2017;100(2):185-92.

[93] Consortium GP, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56.

[94] Lee Y, Nelder JA. Hierarchical generalized linear models. Journal of the Royal Statistical Society: Series B (Methodological). 1996;58(4):619-56.

[95] Meng XL. Decoding the h-likelihood. Statistical Science. 2009;24(3):280-93.

[96] Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS, Miao J, et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. medRxiv. 2020:2020-09.

[97] Boukas L, Bjornsson HT, Hansen KD. Promoter CpG density predicts downstream gene loss-of-function intolerance. The American Journal of Human Genetics. 2020;107(3):487-98.

[98] Pers TH, Karjalainen JM, Chan Y, Westra HJ, Wood AR, Yang J, et al. Biological interpretation of genome-wide association studies using predicted gene functions. Nature Communications. 2015;6(1):5890.

[99] The Gene Ontology resource: enriching a GOld mine. Nucleic acids research. 2021;49(D1):D325-34.

[100] Raina P, Guinea R, Chatsirisupachai K, Lopes I, Farooq Z, Guinea C, et al. GeneFriends: gene co-expression databases and tools for humans and model organisms. Nucleic Acids Research. 2023;51(D1):D145-58.

[101] Consortium G, Ardlie KG, Deluca DS, Segrè AV, Sullivan TJ, Young TR, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648-60.

[102] DGT RPC, Consortium F, et al. A promoter-level mammalian expression atlas. Nature. 2014;507(7493):462-70.

[103] Fulco CP, Nasser J, Jones TR, Munson G, Bergman DT, Subramanian V, et al. Activity-by-contact model of enhancer–promoter regulation from thousands of CRISPR perturbations. Nature Genetics. 2019;51(12):1664-9.

[104] Roadmap EC, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317-30.

[105] Liu Y, Sarkar A, Kheradpour P, Ernst J, Kellis M. Evidence of reduced recombination rate in human regulatory domains. Genome Biology. 2017;18(1):1-11.

[106] Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Research. 2005;15(8):1034-50.

[107] Sullivan PF, Meadows JR, Gazal S, Phan BN, Li X, Genereux DP, et al. Leveraging base-pair mammalian constraint to understand genetic variation and human disease. Science. 2023;380(6643):eabn2937.

[108] Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome research. 2010;20(1):110-21.

[109] Elnaggar A, Heinzinger M, Dallago C, Rehawi G, Wang Y, Jones L, et al. Prottrans: Toward understanding the language of life through self-supervised learning. IEEE Transactions on Pattern Analysis and Machine Intelligence. 2021;44(10):7112-27.

[110] Stärk H, Dallago C, Heinzinger M, Rost B. Light attention predicts protein location from the language of life. Bioinformatics Advances. 2021;1(1):vbab035.

[111] Huang YF. Unified inference of missense variant effects and gene constraints in the human genome. PLoS Genetics. 2020;16(7):e1008922.

4 Methods

Empirical Bayes overview

Many genes have few observed loss-of-function variants, making it challenging to infer constraint without additional information. Bayesian approaches that specify a prior distribution for each gene can provide such information to improve constraint estimates, but specifying prior distributions is challenging as we have limited prior knowledge about the selection coefficients s_{het}. Empirical Bayes procedures allow us to learn a prior distribution for each gene by combining information across genes.

To use the information contained in the gene features, we learn a mapping from a gene's features to a prior specific for that gene. We parameterize this mapping using gradient-boosted trees, as implemented in `NGBoost` [17]. Intuitively, this approach learns a notion of "similarity" between genes based on their features, and then shares information across similar genes to learn how s_{het} relates to the gene features. This approach has two major benefits. First, by sharing information between similar genes, it can dramatically improve the accuracy of the predicted s_{het} values, particularly for genes with few expected LOFs. Second, by leveraging the LOF data, this approach allows us to learn about how the various gene features relate to fitness, which cannot be modeled from first principles.

For a more in-depth description of our approach along with mathematical and implementation details, see Supplementary Note A.

Population genetic likelihood

To model how s_{het} relates to the frequency of individual LOF variants, we used the discrete-time Wright-Fisher model, with an approximation of diploid selection with additive fitness effects. We used a composite likelihood approach, assuming independence across individual LOF variants to obtain gene-level likelihoods. Within this composite likelihood, we model each individual variant as either having a selection coefficient of s_{het} with probability $1 - p_{\text{miss}}$, or having a selection coefficient of 0 with probability p_{miss}. That is, p_{miss} acts as the prior probability that a given variant is misannotated, and we assume that misannotated variants evolve neutrally regardless of the strength of selection on the gene. All likelihoods were computed using new machinery developed in a companion paper [16].

Our model depends on a number of parameters—a demographic model of past population sizes, mutation rates for each site, and the probability of misannotation. The demographic model is taken from the literature [73] with modifications as described in [4]. The mutation rates account for trinucleotide context as well as methylation status at CpGs [12]. Finally, we estimated the probability of misannotation from the data.

For additional technical details and intuition see Supplementary Note B.

Curation of LOF variants

We obtained annotations for the consequences of all possible single nucleotide changes to the hg19 reference genome from [74]. The effects of variants on protein function were predicted using Variant Effect Predictor (VEP) version 85 [75] using GENCODE v19 gene annotations [76] as a reference. We defined a variant as a LOF if it was predicted by VEP to be a splice acceptor, splice donor, or stop gain variant. In addition, predicted LOFs were further annotated using LOFTEE [12], which implements a series of filters to identify variants that may be misannotated (for example, LOFTEE considers predicted LOFs near the ends of transcripts as likely misannotations). For our analyses, we only kept predicted LOFs labelled as High Confidence by LOFTEE, which are LOFs that passed all of LOFTEE's filters.

Next, we considered potential criteria for further filtering LOFs: cutoffs for the median exome sequencing read depth, cutoffs for the mean pext (proportion expressed across transcripts) score [74], whether to exclude variants that fall in segmental duplications or regions with low mappability [77], and whether to exclude variants flagged by LOFTEE as potentially problematic but that passed LOFTEE's primary filters.

We trained models with these filters one at a time and in combination, and chose the model that had the best AUPRC in classifying essential from nonessential genes in mice. The filters we evaluated and chose for the final model are reported in Table 2. Since we used mouse gene essentiality data to choose the filters, we do not further evaluate s_{het} on these data.

We considered genes to be essential in mice if they are heterozygous lethal, as determined by [12] using data from heterozygous knockouts reported in Mouse Genome Informatics [78]. We classify genes as nonessential if they are reported as "Viable with No Phenotype" by the International Mouse Phenotyping Consortium [79] (annotations downloaded on 12/08/22 from `https://www.ebi.ac.uk/mi/impc/essential-genes-search/`).

Parameter(s)	Values	Best
Cutoff for sequencing read depth (median across exomes)	5×, 10×, 20×	20×
Cutoff for mean pext across tissues	0.05, 0.1	0.05
Filter if variant falls in a segmental duplication or low mappability region	True, False	False
Filter if variant is flagged as potentially problematic	True, False	True

Table 2: **Parameters for LOF curation**

Finally, we annotated each variant with its frequency in the gnomAD v2.1.1 exomes [12], a dataset of 125,748 uniformly-analyzed exomes that were largely curated from case–control studies of common adult-onset diseases. gnomAD provides precomputed allele frequencies for all variants that they call.

For potential LOFs that are not segregating, gnomAD does not release the number of individuals that were genotyped at that position. For these sites, we used the median number of genotyped individuals at the positions for which gnomAD does provide this information. We performed this separately on the autosomes and X chromosome.

Data sources for the variant annotations, filters, and frequencies, as well as additional information used to compute likelihoods are listed in Table 3.

Resource	Link
Annotations for possible LOFs	gs://gnomad-public/papers/2019-tx-annotation/pre_computed/all.possible.snvs.tx_annotated.GTEx.v7.021520.tsv
Mean methylation for CpG sites	gs://gcp-public-data--gnomad/resources/methylation
Exome sequencing coverage	gs://gcp-public-data--gnomad/release/2.1/coverage/exomes/gnomad.exomes.coverage.summary.tsv.bgz
Variant frequencies	gs://gcp-public-data--gnomad/release/2.1.1/vcf/exomes/gnomad.exomes.r2.1.1.sites.vcf.bgz
Low mappability and segmental duplications	https://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/genome-stratifications/v3.1/GRCh37/Union/GRCh37_alllowmapandsegdupregions.bed.gz

Table 3: **Sources for LOF data**

Feature processing and selection

We compiled 10 types of gene features from several sources:

1. Gene structure (e.g., number of transcripts, number of exons, GC content)
2. Gene expression across tissues and cell lines
3. Biological pathways and Gene Ontology terms
4. Protein-protein interaction networks
5. Co-expression networks
6. Gene regulatory landscape (e.g., number and properties of enhancers and promoters)
7. Conservation across species
8. Protein embeddings
9. Subcellular localization
10. Missense constraint

Additionally, we included an indicator variable that is 1 if the gene is on the non-pseudoautosomal region of the X chromosome and 0 otherwise.

For a description of the features within each category and where we acquired them, see Supplementary Note C.

Training and validation

We fine-tuned the hyperparameters for our full empirical Bayes approach, using the best hyperparameters from an initial feature selection step (described in Supplementary Note C) as a starting point. To minimize overfitting, we split the genes into three sets—a training set (chromosomes 7-22, X), a validation set for hyperparameter tuning (chromosomes 2, 4, 6), and a test set to evaluate

overfitting (chromosomes 1, 3, 5). During each training iteration, one or more trees were added to the model to fit the natural gradient of the loss on the training set. We stopped model training once the loss on the validation set did not improve for 10 iterations in a row (or the maximum number of iterations, 1,000, was reached). Using this approach, we performed a grid search over the hyperparameters listed in Table 4 and used the combination that minimized the validation loss.

Parameter(s)	Values	Best
Learning rate	0.0125, 0.05, 0.2	0.0125
Maximum tree depth (`max_depth`)	3, 4, 5	3
Data subsampling ratio (`subsample`)	0.6, 0.8, 1	0.8
Minimum weight of a leaf node (`min_child_weight`)	1, 2, 4	1
L1 regularization (`alpha`)	0, 1, 2	2
L2 regularization (`lambda`)	1, 2, 4	1
Number of trees to fit per iteration (`n_estimators`)	1, 2, 4	4

Table 4: `NGBoost` **parameters**

For Figure 2**B**, we reported results from the best model learned using the training set. For all other results, we trained a model on all genes using the hyperparameters and number of training iterations learned during this hyperparameter fine-tuning step.

Choosing genes for Table 1

To identify genes that are considered constrained by s_{het} but not by LOEUF, we filtered for genes with $s_{\text{het}} > 0.1$ (top ∼17% most constrained genes, analogous to the recommended LOEUF cutoff of 0.35 [14], which corresponds to the top ∼16% of genes) and LOEUF > 0.5 (least constrained ∼73% of genes). Of these, we identified genes where heterozygous or hemizygous mutations that decrease the amount of functional protein (e.g. LOF mutations) are associated with Mendelian disorders in the Online Mendelian Inheritance in Man (OMIM) database [36]. We chose genes for Table 1 primarily based on their prominence in the existing literature.

Evaluation on additional datasets

Definition of human essential and nonessential genes

We obtained data from 1,085 CRISPR knockout screens quantifying the effects of genes on cell survival or proliferation from the DepMap portal (22Q2 release) [37, 38]. Scores from each screen are normalized such that nonessential genes identified by Hart et al. [80] have a median score of 0 and that common essential genes identified by [80, 81] have a median score of -1.

In classifying essential genes (Figure 3**A**), we define a gene as essential if its score is < -1 in at least 25% of screens, and as *not* essential if its score is > -1 in all screens. In classifying nonessential genes, we define a gene as nonessential if it has a minimal effect on growth in most cell lines (score > -0.25 and < 0.25 in at least 99% of screens), and as *not* nonessential if its score is < 0 in all screens.

Definition of developmental disorder genes

Through the Deciphering Developmental Disorders (DDD) study [39], clinicians have annotated a subset of genes with the strength and nature of their association with developmental disorders. We classify genes as developmental disorder genes if they are annotated by the DDD study with `confidence_category` = `definitive` and `allelic_requirement` = `monoallelic_autosomal`, `monoallelic_X_hem` (hemizygous), or `monoallelic_X_het` (heterozygous).

We classify genes as not associated with developmental disorders if they are annotated by the DDD study, do not meet the above criteria, and are not annotated with `confidence_category` = `strong` or `moderate` and `allelic_requirement` = `monoallelic_autosomal`, `monoallelic_X_hem`, or `monoallelic_X_het`.

We downloaded genes with DDD annotations from `https://www.deciphergenomics.org/ddd/ddgenes` on 05/06/2023.

Enrichment/depletion of Human Phenotype Ontology (HPO) genes

The Human Phenotype Ontology (HPO) provides a structured organization of phenotypic abnormalities and the genes associated with them, with each HPO term corresponding to a phenotypic abnormality. We calculated the enrichment of constrained genes in each HPO term with at least 200 genes as the ratio (fraction of HPO genes under constraint)/(fraction of background genes under constraint). We defined genes under constraint to be the decile of genes considered most constrained by s_{het} or LOEUF. For background genes, we sampled from the set of all genes to match each HPO term's distribution of expected unique LOFs. Similarly, we calculated the depletion of unconstrained genes in each HPO term as the ratio (fraction of HPO genes not under constraint)/(fraction of background genes not under constraint), where we define genes not under constraint to bethe decile of genes considered least constrained by s_{het} or LOEUF.

We downloaded HPO phenotype-to-gene annotations from `http://purl.obolibrary.org/obo/hp/hpoa/phenotype_to_genes.txt` on 01/27/2023.

Enrichment of *de novo* mutations in developmental disorder patients

We used the enrichment metric developed by [5] in their analysis of *de novo* mutations (DNMs) identified from exome sequencing of 31,058 developmental disorder patients and their unaffected parents. Enrichment of DNMs in developmental disorder patients was calculated as the ratio of observed DNMs in patients over the expected number under a null mutational model that accounts for the study sample size and triplet mutation rate at the mutation sites [82].

For Figure 3**D**, we calculated the enrichment of DNMs in constrained genes, defined as the decile of genes considered most constrained by s_{het} or LOEUF. For Supplementary Figure 2**C**, we calculated the enrichment of DNMs in constrained genes with and without known associations with development disorders. We defined a gene as having a known association if it is annotated by the DDD study (see Methods section "Definition of developmental disorder genes") with `confidence_category` = `definitive` or `strong` and `allelic_requirement` = `monoallelic_autosomal`, `monoallelic_X_hem` (hemizygous), or `monoallelic_X_het` (heterozygous).

For each set of genes, we computed the mean enrichment over sites and 95% Poisson confidence intervals for the mean using the code provided by [5].

Expression variability across species

To understand the variability in expression between humans and other species, we focused on gene expression differences between human and chimpanzee as estimated from RNA sequencing of an *in vitro* model of the developing cerebral cortex for each species [42]. As a metric of variability between the two species, we used the absolute log-fold change (LFC) in gene expression between human and chimpanzee cortical spheroids, which was calculated from samples collected at several time points throughout differentiation of the spheroids. LFC estimates were obtained from [42, Supplementary Table 9].

To visualize the relationship between constraint and absolute LFC, we plotted a LOESS curve between the constraint on a gene (gene rank from least to most constrained using either s_{het} or LOEUF as the constraint metric) and the absolute LFC for the gene. Curves were calculated using the `LOWESS` function from the `statsmodels` package with parameters `frac = 0.15` and `delta = 10`.

Expression variability across individuals

We used the coefficient of variance (CV) as a metric for gene expression variability across individuals, defined as $\text{CV} = \sigma_i / \mu_i$, where σ_i and μ_i are the standard deviation and mean of the expression level of gene i respectively. Here, expression is in units of Transcripts Per Million. We calculated CV using 17,398 RNA-seq samples in the GTEx v8 release [43], with data from 838 donors and 52 tissues/cell lines.

Another potential metric for gene expression variability is the standard deviation for a gene, σ_i. However, as the mean expression for a gene, μ_i, is strongly correlated with σ_i (Spearman $\rho = 0.73$ in GTEx), the relation between σ_i and $s_{\text{het}}^{(i)}$ may be confounded by the relation between μ_i and $s_{\text{het}}^{(i)}$. In contrast, we found that CV is only slightly correlated with μ_i (Spearman $\rho = -0.06$ in GTEx).

LOESS curves were computed as in "Expression variability across species."

Feature interpretation

Training models on feature subsets

We grouped features into categories (see Supplementary Table 4 for the features in each category), and trained a model for each category to predict s_{het} from the corresponding features. For each model, we tuned hyperparameters over a subset of the settings we tuned for the full model (Table 5), and chose the combination of hyperparameters that minimized the loss over genes in the validation set. As a baseline, we trained a model with no features, such that all genes have a shared prior distribution that is learned from the LOF data—this model is analogous to a standard empirical Bayes model.

Parameter(s)	Values
Learning rate	0.0125, 0.05
Maximum tree depth (`max_depth`)	3
Data subsampling ratio (`subsample`)	0.8, 1
Minimum weight of a leaf node (`min_child_weight`)	1
L1 regularization (`alpha`)	0, 1, 2
L2 regularization (`lambda`)	1
Number of trees to fit per iteration (`n_estimators`)	1, 2, 4

Table 5: **Parameters for feature subsets**

Definition of expression feature subsets

We grouped gene expression features into 24 categories representing tissues, cell types, and developmental stage using terms present in the feature names (Table 6).

Category	Terms in the feature (not case sensitive)
Brain	brain, nerve, microglia, hippocampus
Digestive	digestive, gut, gutendoderm, intestine, colon, ileum
Development	development, gastrulation, embryo
Lung	lung, airway
Eye	eye, retina
Endothelium	endothelium
Muscle	muscle
Hair follicle	hairfollicle
Kidney	kidney
Immune	immune, monocytes, nk, tcell, pbmc
Prostate	prostate
Blood	blood, heme, fetalblood
Adipocyte	adipocyte
Heart	heart, aorta
Thymus	thymus
Pancreas	pancreas, islets, pancreasductal
Liver	liver
Testis	testis
Synovial fibroblast	synovialfibroblast
Bladder	bladder
Placenta	placenta
Bone marrow	bonemarrow
CSF	csf
Lymph nodes	lymphnodes

Table 6: **Terms used to define tissues for expression features**

Scoring individual features

To score individual gene features, we varied the value of one feature at a time and calculated the variance in predicted s_{het} as a feature score. In more detail, we fixed each feature to values spanning the range of observed values for that feature (0th, 2nd, ..., 98th, and 100th percentile), such that all genes shared the same feature value. Then, for each of these 51 feature values, we averaged the s_{het} values predicted by the learned priors over all genes, where the

predicted s_{het} for each gene is the mean of its prior. We denote this averaged prediction by $s_{\text{het}}^{(f)}\{p\}$ for some feature f and percentile p. Finally, we define the score for feature f as $\text{score}_f = \text{sd}(s_{\text{het}}^{(f)}\{0\}, s_{\text{het}}^{(f)}\{2\}, ..., s_{\text{het}}^{(f)}\{98\}, s_{\text{het}}^{(f)}\{100\})$, where sd is a function computing the sample standard deviation. In other words, a feature with a high score is one for which varying its value causes high variance in the predicted s_{het}.

For the lineplots in Figures 4**C**-4**F**, we scale the predictions $s_{\text{het}}^{(f)}\{p\}$ for each feature f by subtracting $(s_{\text{het}}^{(f)}\{0\} + s_{\text{het}}^{(f)}\{100\})/2$ from each prediction.

Pruning features before computing feature scores

While investigating the effects of features on predicted s_{het}, we found that including highly correlated features in the model could produce unintuitive results, such as opposite correlations with s_{het} for highly similar features. Therefore, for Figures 4**C**-4**F**, we first pruned the set of features to minimize pairwise correlations between the remaining features. To do this, we randomly kept one feature in each group of correlated features, where such a group is defined as a set of features where each feature in the set has an absolute Spearman $\rho > 0.7$ to some other feature in the set.

For Figures 4**C**-4**F**, we trained models on the relevant features in this pruned set (gene ontology, network, gene regulatory, and gene structure features for Figures 4**C**, 4**D**, 4**E**, and 4**F** respectively). After feature pruning, we found the directions of effect for the features were consistent with their marginal directions of effect.

Data and code availability

GeneBayes and code for estimating s_{het} are available at `https://github.com/tkzeng/GeneBayes`. Posterior means and 95% credible intervals for s_{het} are available in Supplementary Table 2. Posterior densities for s_{het} are available in Supplementary Table 3. A description of the gene features is available in Supplementary Table 4. These supplementary tables are also available at [83], along with likelihoods for s_{het}, LOF variants with misannotation probabilities, and gene features tables.

Supplementary Material

A Empirical Bayes with `NGBoost`

Empirical Bayes overview

In the simplest version of empirical Bayes, we specify the form of the prior distribution and assume that that prior is shared across all genes—for example, for gene i we might assume the prior distribution is $s_{\text{het}}^{(i)} \sim \text{LogitNormal}(\mu, \sigma)$ with density $p_{\mu,\sigma}(s_{\text{het}}^{(i)})$. Where the $\text{LogitNormal}(\mu, \sigma)$ distribution is defined such that $\text{logit}(s_{\text{het}}^{(i)}) = \log(s_{\text{het}}^{(i)}/(1 - s_{\text{het}}^{(i)}))$ is normally distributed with mean μ and variance σ^2. We can then estimate μ and σ using the observed LOF data for each gene, $\boldsymbol{y}_1, \ldots, \boldsymbol{y}_M$, by maximizing the marginal likelihood:

$$\prod_{i=1}^{M} \int_0^1 p\left(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)}\right) p_{\mu,\sigma}\left(s_{\text{het}}^{(i)}\right) \mathrm{d}s_{\text{het}}^{(i)}. \tag{1}$$

Next, we can compute the posterior distribution of $s_{\text{het}}^{(i)}$ for each gene,

$$p\left(s_{\text{het}}^{(i)} \mid \boldsymbol{y}_i\right) = \frac{p\left(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)}\right) p_{\mu,\sigma}\left(s_{\text{het}}^{(i)}\right)}{\int_0^1 p\left(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)}\right) p_{\mu,\sigma}\left(s_{\text{het}}^{(i)}\right) \mathrm{d}s_{\text{het}}^{(i)}}. \tag{2}$$

However, rather than learning the parameters for the prior from only the LOF data, we can also use gene features to learn gene-specific prior parameters, μ_i and σ_i. To do this, we used a machine learning approach, `NGBoost`, to learn functions f and g such that $\mu_i = f(\boldsymbol{x}_i)$ and $\sigma_i = g(\boldsymbol{x}_i)$, where $\boldsymbol{x}_i$ is a vector of gene features associated with gene i. In the next few sections, we will describe how we learned f and g.

`NGBoost`

`NGBoost` (Natural Gradient Boosting) is an approach for training gradient boosted trees to predict the parameters of a probability distribution [17]. Gradient boosted trees are a type of machine learning model typically used to predict outcomes, y, from features, X, producing point estimates such as predicting $\mathbb{E}[y \mid X]$; in contrast, `NGBoost` uses gradient boosted trees to predict $p(y \mid X = \boldsymbol{x})$ by learning parameters of $p(y \mid X = \boldsymbol{x})$ as functions of $\boldsymbol{x}$—in other words, `NGBoost` allows us to learn the full distribution of y conditioned on observing the features $\boldsymbol{x}$.

Specifically, for gene i, we assume the prior distribution is $s_{\text{het}}^{(i)} \sim \text{LogitNormal}(\mu_i, \sigma_i)$, with density $p_{\mu_i,\sigma_i}(s_{\text{het}}^{(i)})$. $\mu_i = f(\boldsymbol{x}_i)$ and $\sigma_i = g(\boldsymbol{x}_i)$ are functions of the vector of gene features $\boldsymbol{x}_i$ (f and g are parameterized as gradient-boosted trees). We chose this distribution as previous work has suggested that $s_{\text{het}}^{(i)}$ is distributed on a logarithmic scale [1, 2, 4], yet, $s_{\text{het}}^{(i)}$ is also bounded between 0 and 1. Both of these properties are enforced by the LogitNormal distribution. In Supplementary Note B, we develop a population genetic likelihood $p(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)})$, where $\boldsymbol{y}_i$ is a vector that represents the observed frequencies of each possible loss of function variant for the gene. Then, with M genes

in the training set, the score that NGBoost maximizes during training is:

$$\sum_{i=1}^{M} S\left(\boldsymbol{y}_i; \mu_i, \sigma_i\right) = \sum_{i=1}^{M} \log p\left(\boldsymbol{y}_i\right) = \sum_{i=1}^{M} \log \left(\int_0^1 p\left(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)}\right) p_{\mu_i,\sigma_i}\left(s_{\text{het}}^{(i)}\right) \mathrm{d}s_{\text{het}}^{(i)} \right). \tag{3}$$

To do this, NGBoost first initializes the parameters of f and g such that all genes have the same prior distribution. Next, NGBoost adopts a gradient descent approach to maximize the score function: for each iteration until training ends, NGBoost first computes the natural gradient of gene i's score with respect to the parameters μ_i and σ_i of $p_{\mu_i,\sigma_i}(s_{\text{het}}^{(i)})$, where the natural gradient of $S = S(\boldsymbol{y}_i; \mu_i, \sigma_i)$, is defined as:

$$\widetilde{\nabla} S \propto \mathcal{I}_{\mu_i,\sigma_i}^{-1} \nabla_{\mu_i,\sigma_i} S \tag{4}$$

where

$$\mathcal{I}_{\mu_i,\sigma_i} = \mathbb{E}_{s_{\text{het}}^{(i)} \sim p_{\mu_i,\sigma_i}} \left[\left(\nabla_{\mu_i,\sigma_i} \log p_{\mu_i,\sigma_i}\left(s_{\text{het}}^{(i)}\right) \right) \left(\nabla_{\mu_i,\sigma_i} \log p_{\mu_i,\sigma_i}\left(s_{\text{het}}^{(i)}\right) \right)^T \right] \tag{5}$$

is the Fisher Information Matrix for $p_{\mu_i,\sigma_i}(s_{\text{het}}^{(i)})$ and ∇_{μ_i,σ_i} represents differentiation with respect to μ_i and σ_i. Natural gradients take into account the underlying "information geometry" of the space of distributions in a way that standard gradients do not [84]. As an example, changing the variance of a Normal distribution from 0.1 to 0.2 is much more dramatic than changing the variance from 10.1 to 10.2. After computing the natural gradient, NGBoost fits a decision tree to each dimension of the natural gradient, updating μ_i and σ_i in the direction that most steeply increases the gene's score. While gradient-boosting algorithms (including NGBoost, by default) typically fit a single decision tree at each iteration, we allow NGBoost to fit one or more trees, which performs slightly better in practice (see "Training and Validation" in Methods).

Below, we summarize the training algorithm. Let $\mu_i^{(t)}, \sigma_i^{(t)}$ denote the parameters of the prior at training iteration t.

1. Initialize parameters for all genes, $i = 1, ..., M$:
   $\mu_i^{(0)}, \sigma_i^{(0)} = \text{argmax}_{\mu,\sigma} \sum_{i=1}^{M} S(\boldsymbol{y}_i; \mu, \sigma)$
2. For iterations $t = 1, ..., T$:
   (a) For each gene, calculate natural gradients of the score:
   $\widetilde{\nabla} S\left(\boldsymbol{y_i}; \mu_i^{(t)}, \sigma_i^{(t)}\right)$, whose two components we denote as $\widetilde{\nabla} S_\mu$ and $\widetilde{\nabla} S_\sigma$
   (b) Fit decision trees $f^{(t)}$ and $g^{(t)}$ on the natural gradients:
   $f^{(t)} = \text{fit}\left(\left\{ \boldsymbol{x}_i, \widetilde{\nabla} S_{\mu_i} \right\}_{i=1}^{M} \right)$
   $g^{(t)} = \text{fit}\left(\left\{ \boldsymbol{x}_i, \widetilde{\nabla} S_{\sigma_i} \right\}_{i=1}^{M} \right)$
   (c) Update the parameters for each gene, where η is a learning rate that is chosen by the user as a hyperparameter
   $\mu_i^{(t)} = \mu_i^{(t-1)} - \eta f^{(t)}(\boldsymbol{x}_i)$
   $\sigma_i^{(t)} = \sigma_i^{(t-1)} - \eta g^{(t)}(\boldsymbol{x}_i)$

Once training is complete, we obtain a learned prior with parameters $\mu_i^{(T)}, \sigma_i^{(T)}$, and can compute the posterior distribution of s_{het}

$$p\left(s_{\text{het}}^{(i)} \mid \boldsymbol{y}_i\right) = \frac{p\left(\boldsymbol{y}_i \mid s_{\text{het}}^{(i)}\right) p_{\mu_i^{(M)}, \sigma_i^{(M)}}\left(s_{\text{het}}^{(i)}\right)}{p\left(\boldsymbol{y}_i\right)} \tag{6}$$

as well as the mean of this distribution

$$\mathbb{E}\left[s_{\text{het}}^{(i)} \mid \boldsymbol{y}_i\right] = \int_0^1 s_{\text{het}}^{(i)} p(s_{\text{het}}^{(i)} \mid \boldsymbol{y}_i) \mathrm{d}s_{\text{het}}^{(i)} \tag{7}$$

To compute 95% Credible Intervals, we compute the CDF of the posterior distribution using Pytorch's `cumulative_trapezoid` function [85]. Then, the 95% Credible Interval per gene is defined as $[\text{lb}^{(i)}, \text{ub}^{(i)}]$ such that $P(s_{\text{het}}^{(i)} < \text{lb}^{(i)}) = 0.025$ and $P(s_{\text{het}}^{(i)} < \text{ub}^{(i)}) = 0.975$.

`NGBoost`— implementation details

To initialize parameters (step 1 in the training algorithm), we perform gradient descent with the AdamW optimizer [86] implemented in `PyTorch` [85] with the default settings and a learning rate of 5×10^{-4}. We initialize the optimization at $\mu = -5$ and $\sigma = 0.5$.

To compute the integrals in the score calculation, we use the `torchquad` package for numerical integration [87], which allows us to use `PyTorch`'s automatic differentiation system to compute gradients. We perform integration using Boole's rule, integrating from 5×10^{-8} to $1 - 5 \times 10^{-8}$ with 10^6 sample points.

The Fisher Information Matrix is approximated using a Monte Carlo approach: we sample s_{het} from the prior 1,000 times, compute the gradient for each sample, and approximate the expectation using the sample mean.

To flexibly fit decision trees at each training iteration, we use the `XGBoost` package, a library used for fitting standard gradient boosted trees [88]. In comparison to the default `NGBoost` learner, `XGBoost` supports missing features and allows for adjustment of numerous hyperparameters (see "Training and Validation" in Methods). In contrast to typical applications of `XGBoost`, we only allow a few (1-4) trees to be fit at each training iteration, as we are using `XGBoost` within a training loop rather than as a standalone approach for model fitting.

All distributions were implemented using `PyTorch`, and training was conducted with GPU support when available, with `tree_method = "gpu_hist"` for the `XGBoost` learners.

B Population Genetics Model

Overview of model

Some of the most commonly used measures of gene constraint (pLI [11], LOEUF [12]) are framed in terms of the number of unique LOFs observed in gene, O, relative to the number expected under a null model, E. While operationalizing constraint as some function of O and E captures the intuition that seeing fewer LOFs than expected is evidence that a gene is conserved, the numerical values of pLI and LOEUF are difficult to interpret. In practice this means that such measures can be useful for ranking which genes are important, but it makes it difficult to contextualize these results in terms of other types of variants, such as missense or noncoding variants, or copy number variants. Previous approaches have pioneered using a population genetics model in this context to obtain interpretable estimates, albeit with different technical details that we discuss below [1,2,4].

In order to obtain a more interpretable measure of constraint, we formalize constraint as the strength of natural selection acting against gene loss-of-function in a population genetics model. That is, we can ask how much fitness is reduced on average for an individual with one or two non-functional copies of a gene relative to individuals with two functional copies, following previous work [1,2,4]. To tie this concept of constraint to observed allele frequency data, we use a slightly simplified version of the discrete-time Wright Fisher model. This model contains mutation, selection, and genetic drift, and assumes that there are only two alleles and that the population is panmictic, monoecious, and has non-overlapping generations. While all of these assumptions are violated in humans (there are four nucleotides, population structure, two sexes, and overlapping generations), the model still provides a good approximation to allele frequency dynamics through time. If the allele frequency in generation k is f_k, then we model the allele frequency in the next generation via binomial sampling:

$$2N_{k+1}f_{k+1} \sim \text{Binomial}\left(2N_{k+1}, p\left(f_k\right)\right), \tag{8}$$

where N_{k+1} is the number of diploid individuals in generation $k+1$, with

$$p(f_k) := \frac{(1-s_{\text{het}})\widetilde{f}_k\left(1-\widetilde{f}_k\right) + (1-s_{\text{hom}})\widetilde{f}_k^{\,2}}{\left(1-\widetilde{f}_k\right)^2 + 2(1-s_{\text{het}})\widetilde{f}_k\left(1-\widetilde{f}_k\right) + (1-s_{\text{hom}})\widetilde{f}_k^{\,2}},$$

where $\widetilde{f}_k = f_k(1-\mu_{1\to 0}) + \mu_{0\to 1}(1-f_k)$ is the allele frequency after alleles change from non-LOF to LOF at rate $\mu_{0\to 1}$ and from LOF to non-LOF at rate $\mu_{1\to 0}$. The function $p(\cdot)$ arises from considering bidirectional mutation and approximating a model of diploid selection where the relative reproductive success of individuals with 0, 1, or 2 copies of the LOF are 1, $1-s_{\text{het}}$, and $1-s_{\text{hom}}$ respectively [13]. In practice, most LOF variants are extremely rare, and so it is exceedingly unlikely to find individuals homozygous for the LOF. This makes estimating s_{hom} as a separate parameter very difficult, and so we instead assume that $s_{\text{hom}} = \min\{2s_{\text{het}}, 1\}$. This is equivalent to assuming genic selection (i.e., additive fitness effects) with the constraint that an individual's relative fitness cannot be lower than 0.

Equation 8 fully specifies the model except for an initial condition. That is, we need to know what the distribution of frequencies is in generation 0. One mathematically appealing choice

would be to assume that the population is at equilibrium at time 0, but this seemingly straightforward choice results in nonsensical conclusions. To see why, if the mutation rates are low and selection is negligible, then at equilibrium, with extremely high probability the population will either be in a state where the frequency of the LOF allele is very close to zero or in a state where the frequency of the LOF allele is very close to one. If the mutation rates between the two alleles are close to equal, then these two cases happen roughly equally often. That is, we would expect there to be a $\sim$50% chance that the population is fixed or nearly fixed for the LOF mutation. If there are multiple independently evolving sites at which an LOF could arise (or if there are many more ways to mutate to an LOF state than a non-LOF state), then the chance that any of these sites is fixed or nearly fixed for an LOF rapidly approaches 100%. Under this equilibrium assumption, we thus reach the absurd conclusion that the mere act of observing a gene that is functional in a majority of the population is overwhelming evidence that the gene is strongly selected for. Another way of viewing this is that in reality we can only observe genes that are functional in an appreciable fraction of the population, and so we should somehow be conditioning on this event, whereas the equilibrium assumption looks at a given randomly chosen stretch of DNA and asks whether it could be a gene given some set of mutations. Indeed, any randomly chosen stretch of DNA could be made a gene through a series of mutations, but for any given stretch it would be extremely unlikely to be a functional gene, and the equilibrium assumption exactly captures how rare this would be.

We instead use the equilibrium of another process as the initial condition, which avoids these conceptual pitfalls. We assume the distribution of frequencies at generation 0 is the equilibrium conditioned on the LOF allele never reaching fixation in the population. We then compute the likelihood of observing a given present-day frequency while continuing to condition on non-fixation of the LOF allele. This assumption implies that no matter the current frequency of the LOF variant, we know that at some point in the past the population was fixed for the functional version of the gene, and the LOF variant can thus be thought of as being "derived" and the non-LOF variant "ancestral". In the limit of infinitely low (but non-zero) mutation rates, this assumption become equivalent to the commonly assumed "infinite sites" model commonly used to compute frequency in population genetics [89]. In contrast to the infinite sites model, where the probability that any given site is segregating must be 0, our model allows us to compute the probability that a given site is segregating. Furthermore, we can easily model recurrent mutation which can be important for sites with large mutation rates (such as CpGs) and large sample sizes [90], whereas under the infinite sites model each mutation necessarily happens at a unique position in the genome, ruling out the possibility of recurrent mutation. Below we will write $p_{\text{DTWF}}(y \mid s_{\text{het}})$ for the probability mass function computed using this procedure, with "DTWF" representing Discrete-Time Wright-Fisher, and y being an observed LOF allele frequency.

Equation 8 is easy to describe and simulate under, and a very similar model has been used in an approximate Bayesian computation approach to estimate s_{het} [4]. While simulation is easy, computing likelihoods under this model is difficult for large sample sizes, and unfortunately we need explicit likelihoods in our empirical Bayes approach. In recent work [16], we have developed an efficient method for computing likelihoods under this model. The key idea is that the above dynamics can be written as

$$\mathbf{v}_{k+1} = \mathbf{M}_k^T \mathbf{v}_k$$

where $\mathbf{v}_k$ is a vector of dimension $2N + 1$ where entry i is the probability that there are i haploids

that have the LOF allele in generation k, and $\mathbf{M}_k$ is a matrix where row i is the the probability mass function of the Binomial distribution in Equation 8 given that the allele frequency in generation k is $i/2N_k$. This formulation makes clear that we can obtain the likelihood of observing a given frequency at present given some initial distribution by performing a series of matrix-vector multiplications. Naively this would be prohibitively slow as $\mathbf{M}_k$ can be as large as $10^7 \times 10^7$, but in [16] we show that $\mathbf{M}_k$ is approximately highly structured — it is both approximately extremely sparse and approximately extremely low rank. Combining these insights we can perform matrix-vector multiplication that is provably accurate while reducing the runtime for matrix-vector multiplication from $O(N_k^2)$ to $O(N_k)$. Similar insights can be used to speed up the computation of equilibria, which we discuss in detail in [16]. Furthermore, as discussed above, we actually want to compute likelihoods conditioned on non-fixation of the LOF allele, but that is as simple as setting the column of $\mathbf{M}_k$ corresponding to fixation to 0, and then renormalizing $\mathbf{v}$. We precompute these likelihoods for each possible pair of mutation rates (to and from the LOF allele) across a range of s_{het} values (100 log-linearly spaced points between 10^{-8} and 1, as well as 0). We describe how we set the mutation rates and the population sizes implicit in $\mathbf{M}_k$ below.

Modeling misannotation of LOFs

Under the likelihood described above, and as seen in Figure 2**A**, positions where a LOF variant could occur, but no LOF alleles are observed are slight evidence in favor of selection, while high frequency variants are extremely strong evidence against selection. Meanwhile, we suspect that many variants that are annotated as causing LOF actually have little to no effect on the gene product due to some form of misannotation. If these misannotated variants evolve effectively neutrally, they can reach high frequencies and cause us to artifactually infer artificially low levels of selection. These misannotated variants can be particularly problematic for approaches that combine frequencies across all LOFs within a gene to obtain an aggregate gene-level LOF frequency [1,2,4].

LOEUF [12] and pLI [11] avoid this problem by throwing away all frequency information except for whether an LOF is segregating or not. While this approach is more robust, the ignored frequency information is extremely useful for estimating the strength of selection. For example, consider a gene where we expect to see 5 unique LOFs under neutrality and we see 3 segregating LOFs. This might seem like weak or negligible constraint (O/E = 0.6), but if those 3 sites are all highly mutable and the variants at those sites are each only present in a single individual, then it is plausible that this gene is quite constrained.

To take full advantage of the information in the LOF frequencies while remaining robust to misannotation, we take a composite likelihood approach [91], closely related to the Poisson random field assumption commonly used in population genetics [89]. We approximate gene-level likelihoods as a product of variant level likelihoods

$$p^{(i)}\left(\boldsymbol{y}^{(i)} \mid s_{\text{het}}^{(i)}\right) \approx \prod_{j=1}^{J_i} p_{\text{variant}}\left(\boldsymbol{y}_j^{(i)} \mid s_{\text{het}}^{(i)}\right),$$

where $\boldsymbol{y}^{(i)}$ is a vector of the observed allele frequencies at each possible LOF site in gene i, and $s_{\text{het}}^{(i)}$ is the selection coefficient for having a heterozygous loss-of-function of gene i. Under this formulation, we can easily model misannotation by assuming that each LOF independently has

some probability of being misannotated, p_{miss}, and that misannotated variants evolve neutrally:

$$p_{\text{variant}}\left(\mathbf{y}_j^{(i)} \mid s_{\text{het}}^{(i)}\right) = (1 - p_{\text{miss}})p_{\text{DTWF}}\left(\mathbf{y}_j^{(i)} \mid s_{\text{het}}^{(i)}\right) + p_{\text{miss}}p_{\text{DTWF}}\left(\mathbf{y}_j^{(i)} \mid 0\right).$$

Using this formulation, we can take full advantage of the rich information included in the exact sample frequencies of each LOF variant, while still being robust to occasional misannotation. In practice, we precompute p_{variant} using a grid of p_{miss} values, and then to obtain the likelihood at arbitrary values of s_{het} and p_{miss} we linearly interpolate in log-likelihood space. Below, we discuss our approach for setting p_{miss}.

Given a probability of misannoation, we can then calculate a posterior probability that any given variant has been misannotated. We include a table of these misannotation probabilities for all possible LOFs in Supplementary Table XXX.

As an example of the importance of correcting for misannotation, we consider the case of the gene PPFIA3 (ENSG00000177380). This gene has a LOEUF score of 0.12 and so appears very constrained, but in an early version of our model where we did not incorporate variant misannotation, we inferred a posterior mean value of s_{het} of $\sim 2 \times 10^{-4}$, which is right at the border of being nearly neutral. Inspecting the LOF data for this gene, we find that all potential LOFs are either not observed or observed in a single individual, except for a single splice donor-disrupting variant at 16% frequency. There are no obvious signs indicating that this variant is misannotated (e.g., in terms of coverage or mappability). If we model misannotation, however, we find that this variant is likely misannotated (posterior probability of misannotation > 99.999%), and as a result we estimate extremely strong selection against gene loss-of-function (posterior mean s_{het} of $\sim$ 0.234). Indeed, a single autosomal dominant missense variant in this gene is suspected to have caused a number of severe symptoms including developmental delay, intellectual disability, seizures, and macrocephaly in an Undiagnosed Diseases Network participant (`https://undiagnosed.hms.harvard.edu/participants/participant-159/`) [92].

Modeling the X chromosome

We must slightly modify our model when applying it to the X chromosome. Because males only have one copy of the X chromosome, there are only 3/4 as many X chromosomes as autosomes (assuming an approximately equal sex ratio). As a result, when dealing with the X chromosome we scale all population sizes to 3/4 of the size used for the autosomes (rounded to the nearest integer). We also need to slightly modify the expected frequency in the next generation. We assume haploid selection in males with strength s_{hom}, and diploid selection in females with selection coefficients s_{het} and s_{hom} for individuals heterozygous and homozygous for the LOF variant respectively. This selection results in modified allele frequencies in the pool of males and females, and the we assume that each chromosome in the next generation has 1/3 probability of coming from a male, and 2/3 probability of coming from a female. This means that the expected frequency in the next generation is 1/3 times the post-selection frequency in males plus 2/3 times the post-selection frequency in females. Variants within the pseudoautosomal regions on the X are modeled identically to variants on the autosomes. Agarwal and colleagues also considered selection on the X in the context of LOF variants, with a model similar to that described here [4].

Model parameters

Our model has three key parameters — the mutation rate, the demographic model (i.e., population sizes through time), and the probability that different variants are misannotated.

We obtained mutation rates from gnomAD [12, Supplemental Dataset 10], which take into account trinucleotide context and methylation level (for CpG to TpG mutations). In our population genetics model, we assume that there are only two alleles (a functional allele and an LOF allele), whereas in reality there are four nucleotides. We approximate the rate of mutating from the functional allele to the LOF allele as being the sum of the mutation rates from the reference nucleotide to any nucleotide that might result in LOF. For example, if the reference allele is A, and either a C or a T would result in LOF, then we say that the rate at which the functional allele mutates to the LOF allele is the rate at which A mutates to C in this context plus the rate at which A mutates to T in this context. For the rate of back mutation from the LOF allele to the functional allele, we compute a weighted average of the rates of each possible LOF nucleotide back-mutating to any possible non-LOF nucleotide, weighed by the probability that the original non-LOF nucleotide mutated to that particular LOF nucleotide. Continuing our previous example, suppose A mutates to C at rate 1×10^{-8} and A mutates to T at a rate 1.5×10^{-8}. Then conditioned on there having been a single mutation resulting in a LOF variant, there is a $1/2.5 = 0.4$ chance that the LOF is C and 0.6 chance that the LOF is T. We then compute the back mutation rate as 0.4 times the rate at which C mutates to A in this context plus the rate at which C mutates to G in this context (since both A and G do not result in LOF) plus 0.6 times the rate at which T mutates to A in this context plus the rate at which T mutates to G in this context. Implicitly this scheme assumes that the flanking nucleotides in the trinucleotide context do not change, and we further assume that all mutations resulting in CpGs result in unmethylated CpGs.

For the population sizes in each generation, we used the "CEU" model inferred in [73] using the 1000 Genomes Project data [93]. This model was also used in [4]. Population sizes under this model are relatively constant before 5156 generations ago (approximately 155 thousand years ago) and the effects of strong selection are relatively insensitive to all but the most recent population sizes, so for a computational speedup we assumed that the population size was constant prior to 5156 generations ago. Recently, [4] found that this CEU model underestimates the number of low frequency variants and that changing the population size to 5,000,000 for the most recent 50 generations provides a better fit to the data. We used both demographic models and found qualitatively similar results, with slightly better fit provided by the modified model, so we used that demographic model for all subsequent analyses. In both cases, we modified the most ancient population sizes, which are relatively constant, to be actually constant to speed up likelihood calculations. The demographic models are presented in Supplementary Figure 1.

The only remaining model parameter is p_{miss} the probability that any given LOF is misannotated. Throughout we focus on LOFs that either introduce early stop codons, disrupt splice donors, or disrupts splice acceptors. Given that predicting which variants have these different consequences involves different bioinformatic challenges, we inferred separate misannoatation probabilities p^c_{miss} for $c \in \{\text{stop codon}, \text{splice donor}, \text{splice acceptor}\}$. Below we write p_{miss} for the collection of these three misannotation parameters. To get a rough estimate of these parameters and avoid excessive computational burden, we took an h-likelihood approach [94, 95]. That is, we jointly maximized the likelihood across all genes with respect to their selective constraints as well



Supplementary Figure 1: CEU Demography inferred by Schiffels and Durbin [73], modified by Agarwal and colleagues [4], and further modified for this paper.

as the the three misannotation probabilities that are shared across all genes:

$$\max_{p_{\text{miss}}, s_{\text{het}}^{(1)}, \ldots, s_{\text{het}}^{(M)}} \sum_{i=1}^{M} \log p\left(\mathbf{y}^{(i)} \mid s_{\text{het}}^{(i)}, p_{\text{miss}}\right).$$

This approach of just using the maximum likelihood estimates of s_{het} for each gene contrasts with the standard empirical Bayes approach, which would involve marginalizing out the unknown s_{het} values. Yet, this marginalization step depends on the prior on s_{het}, which we learn via our `NGBoost` framework. As a result, we would need to repeatedly run our `NGBoost` framework as an inner loop to perform the standard empirical Bayes approach on p_{miss}. For our application, these values are nuisance parameters, and the results are relatively insensitive to their exact values so we opted for this simpler h-likelihood approach. Ultimately, we estimate that the probability of misannotation is 0.7%, 6.1%, and 8.4% for stop codons, splice donors, and splice acceptors respectively.

C Feature processing and selection

We compiled 10 types of gene features from several sources:

1. *Gene structure.* Gene structure features were derived from GENCODE gene annotations (Release 39) [76]. Such features include the number of transcripts and, for the primary transcript of each gene (the transcript tagged `Ensembl_canonical`), the number of exons as well as the length and GC content of the transcript, total coding region, 5′ UTR, and 3′ UTR.

2. *Gene expression.* We used gene features from 77 bulk and single-cell RNA-seq datasets, processed and derived in [96]. These datasets can be grouped into 24 categories representing tissues, cell types, and developmental stage (Table 6). For each dataset, features were derived separately from all data and from individual cell clusters (for example, gene loadings on principal components). In addition, features were derived from comparisons between clusters (for example, t-statistics for differential expression). Finally, we include a metric, τ, that summarizes the tissue-specificity of gene expression [97].

3. *Biological pathways and Gene Ontology terms.* First, we included previously curated biological pathway features [96, 98]. In addition, to include GO terms that capture additional known relationships between genes, we downloaded Biological Pathway (BP), Molecular Function (MF), and Cellular Component (CC) terms [99] with at least 10 member genes using the procedure described in [10]. Features for each gene were encoded as binary indicators of the gene's membership in the pathways and GO terms.

4. *Connectedness in protein-protein interaction (PPI) networks.* We included previously computed measures of the connectedness of protein products of genes in PPI networks [10]. Connectedness was calculated as the number of interactions per protein weighted by the interaction confidence scores.

5. *Co-expression.* First, we included previously computed measures of the connectedness of genes in co-expression networks [10], where connectedness measures the relative number of neighbors of each gene in the network, averaged over tissues. Next, for each gene, we derived features representing its co-expression with other genes (i.e. correlation in their expression levels across samples). To do this, we downloaded from the GeneFriends database a co-expression network derived from GTEx RNA-seq samples [100,101], calculated the variance in the co-expression for each gene, and kept the 6,000 most variable genes. Then, we included the co-expression with each of these 6,000 genes as a feature.

6. *Gene regulatory landscape.* Gene regulatory features include the counts and properties of the enhancers and promoters that regulate each gene. First, we included the number of promoters per gene estimated by the FANTOM consortium using Cap Analysis of Gene Expression [10, 102]. Next, for each gene, we calculated the number, summed length, and summed score of enhancer-to-gene links predicted using the Activity-By-Contact (ABC) approach [49,103], where an enhancer is considered linked to a gene if its ABC score is ≥ 0.015. We computed separate features for each of 131 biosamples. We also included features derived by aggregating over all biosamples for both ABC enhancers and predicted enhancers

from the Roadmap Epigenomics Consortium [10, 104, 105]—these feature include the number of biosamples with an active enhancer element, the total number of enhancer elements, the total number of enhancer elements after taking merging enhancer domains, the total length of the merged domains, and the average total enhancer length in an active cell type. Finally, we included the enhancer-domain score for each gene [9] as a feature.

7. *Conservation across species.* For each gene, we calculated the mean and 95th percentile phastCons scores over the gene's exons for multiple alignments of 7, 17, 20, 30, and 100 vertebrate species to the human genome [106]. We downloaded phastCons Scores from `https://hgdownload.soe.ucsc.edu/goldenPath/hg38/`. In addition, we included the fraction of coding sequence (CDS) or exons constrained across 240 mammals or 43 primates sequenced in the Zoonomia project [107], with constraint determined by the per-base phyloP [108] or phastCons score. Zoonomia data were downloaded from `https://figshare.com/articles/dataset/geneMatrix/13335548`.

8. *Protein embedding features.* We included as features the embeddings learned by an autoencoder (ProtT5) trained on protein sequences [109]. Embeddings were downloaded from `https://zenodo.org/record/5047020`. The embedding for each protein is a fixed-size vector that captures some of the protein's biophysical and functional properties. For each gene with more than one protein product, we averaged the embeddings of the proteins for that gene.

9. *Subcellular localization.* We included as features the subcellular localization of each protein and whether the protein is membrane-bound or soluble, as predicted by deep neural networks trained on the ProtT5 protein embeddings [109, 110]. Possible subcellular classes included nucleus, cytoplasm, extracellular space, mitochondrion, cell membrane, endoplasmatic reticulum, plastid, Golgi apparatus, lysosome or vacuole, and peroxisome. Predictions were one-hot encoded, and for each gene with more than one protein product, we summed the predictions for the gene's proteins. Predictions were downloaded from `https://zenodo.org/record/5047020`.

10. *Missense constraint.* We included a measure of each gene's average intolerance to missense variants (UNEECON-G score) [111]. UNEECON-G scores incorporate variant-level features to account for differences in the effects of missense variants on gene function.

In addition to these 10 groups of features, we included a binary indicator for whether the gene is located on the X chromosome. Genes in the pseudoautosomal regions were categorized as autosomal.

After compiling these features (total of 65,383), we performed feature selection to minimize the practical complexity of training on such a large feature set and the complexity of the resulting model. First, we removed features with zero variance and features where the Spearman correlation of the feature values with O/E (the ratio of observed over expected unique LOF variants, computed using gnomAD data) was less than 0.1 or had a nominal p-value ≥ 0.05. Next, we performed simultaneous feature selection and an initial round of hyperparameter tuning using the `shap-hypetune` package, which uses Bayesian optimization to identify a set of features and hyperparameters that minimize the loss of a machine learning model fit on the training data. Specifically, we fit gradient-boosted trees using `XGBoost` to predict O/E from the gene features; we chose to

perform feature selection using `XGBoost` rather than `NGBoost` as training `XGBoost` models is substantially faster, and because we expect features/hyperparameters that perform well for `XGBoost` to also perform well for `NGBoost`. For each set of hyperparameters, `shap-hypetune` performs backward step-wise selection by removing the k least influential features (we chose $k = 1000$ and calculated influence using SHAP scores) at each step. Finally, we performed further feature selection using `shap-hypetune` by fixing the hyperparameters and performing backward step-wise selection with $k = 50$. Ultimately, we included 1,248 features in the model.

D Estimating additional gene properties using GeneBayes

GeneBayes is a flexible framework that can be used to infer other gene-level properties of interest beyond s_{het}. In Figure 6, we presented a schematic of the key components of GeneBayes that users should specify, which we describe in more detail now.

First, users should specify the gene features to use as predictors. We expect the gene features we use for s_{het} estimation to work well for other applications, but GeneBayes supports any choice of features. In particular, GeneBayes can handle categorical and continuous features without feature scaling, as well as features with missing values.

Next, users should specify the form of the prior distribution. GeneBayes supports the distributions defined by the `distributions` package of `PyTorch`. GeneBayes also supports custom distributions, as long as they implement the methods used by GeneBayes (i.e. `log_prob` and `sample`) and are differentiable within the `PyTorch` framework.

Finally, users need to specify a likelihood function that relates their gene property of interest to observed data. The likelihood can be specified in terms of a `PyTorch` distribution, or as a custom function.

After model training, GeneBayes outputs a per-gene posterior mean and 95% credible interval for the property of interest. For each parameter in the prior, GeneBayes also outputs a metric for each feature that represents the contribution of the feature to predictions of the parameter.

In the next section, we describe in more detail the two example applications that we outlined in Figure 6.

Example applications

Differential expression

In this example, users have estimates of log-fold changes in gene expression between conditions and their standard errors from a differential expression workflow, and would like to estimate log-fold changes with greater power (e.g. for lowly-expressed genes with noisy estimates).

Likelihood We define $\ell_{\text{DE}}^{(i)}$ and ℓ_i as the estimated and true log-fold change in expression respectively for gene i, and s_i as the standard error for the estimate. Then, we define the likelihood for ℓ_i as

$$\ell_{\text{DE}}^{(i)} \mid \ell_i \sim \text{Normal}(\ell_i, s_i^2).$$

Prior We describe two potential priors that one may choose to try. The first is a normal prior with parameters μ_i and σ_i:

$$\ell_i \sim \text{Normal}(\mu_i, \sigma_i^2).$$

The second is a spike-and-slab prior with parameters π_i, μ_i, and σ_i, which assumes that gene i

only has a π_i probability of being differentially expressed:

$$z_i \sim \text{Bernoulli}(\pi_i)$$
$$\ell_i | z_i \sim \begin{cases} 0, & \text{if } z_i = 0 \\ \text{Normal}(\mu_i, \sigma_i^2), & \text{if } z_i = 1 \end{cases}$$

Variant burden tests

In this example, users have sequencing data from patients with a disease or (if calling *de novo* mutations) sequencing data from family trios, and would like to identify genes with excess mutational burden in patients (e.g. an excess of missense or LOF variants). One approach is to infer the relative risk for each gene (denoted as γ_i for gene i), defined as the expected ratio of the number of variants in patients to the number of variants in healthy individuals.

Likelihood Let E_i be the number of variants we expect to observe for gene i given the study sample size and sequence-dependent mutation rates (e.g. expected counts obtained using the mutational model developed by [82]). Next, let O_i be the number of variants observed in patients for gene i. Then, we define the likelihood for η_i as

$$O_i \mid \eta_i \sim \text{Poisson}(\eta_i E_i).$$

Prior Because η_i is non-negative, one may want to choose a gamma prior with parameters α_i and β_i:

$$\eta_i \sim \text{Gamma}(\alpha_i, \beta_i).$$

Gene	s_{het}	LOEUF
RPL11	0.75	0.3
RPL18	0.72	0.28
RPL5	0.71	0.17
RPL35A	0.67	0.41
RPL15	0.61	0.27
RPL26	0.61	0.38
RPS15A	0.61	0.56
RPS7	0.60	0.31
RPS10	0.60	0.27
RPS26	0.58	0.48
RPL27	0.56	0.48
RPS24	0.48	0.59
RPS29	0.40	1.2
RPS27	0.31	0.64
RPS28	0.26	0.8
RPL35	0.25	0.72

Supplementary Table 1: **LOEUF and s_{het} for ribosomal proteins**



Supplementary Figure 2: **Additional validation analyses. A)** *Precision-recall curves comparing the performance of* s_{het} *estimates from GeneBayes against other constraint metrics in classifying non-essential genes.* **B)** *Precision-recall curves comparing the performance of* s_{het} *against other constraint metrics in classifying developmental disorder genes.* **C)** *Enrichment of de novo mutations in patients with developmental disorders, calculated as the observed number of mutations over the expected number under a null mutational model. We plot the enrichment of missense, splice, and nonsense variants in the 10% of genes considered most constrained by* s_{het} *(blue) and in all other genes (gray), including (left) and excluding (right) known developmental disorder genes. Bars represent 95% confidence intervals.*